WO2012112440A2 - Fluorescent potassium ion sensors - Google Patents
Fluorescent potassium ion sensors Download PDFInfo
- Publication number
- WO2012112440A2 WO2012112440A2 PCT/US2012/024856 US2012024856W WO2012112440A2 WO 2012112440 A2 WO2012112440 A2 WO 2012112440A2 US 2012024856 W US2012024856 W US 2012024856W WO 2012112440 A2 WO2012112440 A2 WO 2012112440A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- poly
- group
- nanoparticle
- copolymer
- Prior art date
Links
- 229910001414 potassium ion Inorganic materials 0.000 title claims abstract description 64
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 150000001875 compounds Chemical class 0.000 claims abstract description 175
- 239000000178 monomer Substances 0.000 claims abstract description 60
- 229920000642 polymer Polymers 0.000 claims abstract description 59
- 239000002105 nanoparticle Substances 0.000 claims abstract description 52
- 229920005604 random copolymer Polymers 0.000 claims abstract description 33
- 239000010409 thin film Substances 0.000 claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims description 148
- -1 poly(N-isopropyl acrylamide) Polymers 0.000 claims description 128
- 239000010408 film Substances 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 60
- 230000008685 targeting Effects 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 47
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 38
- 150000003839 salts Chemical group 0.000 claims description 38
- 239000000758 substrate Substances 0.000 claims description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 27
- 239000001301 oxygen Substances 0.000 claims description 27
- 125000005647 linker group Chemical group 0.000 claims description 26
- 229920002401 polyacrylamide Polymers 0.000 claims description 24
- 229920001577 copolymer Polymers 0.000 claims description 21
- 239000011724 folic acid Substances 0.000 claims description 21
- 229960000304 folic acid Drugs 0.000 claims description 21
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 19
- 235000019152 folic acid Nutrition 0.000 claims description 19
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000011521 glass Substances 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 229920000249 biocompatible polymer Polymers 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 12
- 239000004800 polyvinyl chloride Substances 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- 108091023037 Aptamer Proteins 0.000 claims description 9
- 101710164760 Chlorotoxin Proteins 0.000 claims description 9
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims description 9
- 229960005534 chlorotoxin Drugs 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 238000003384 imaging method Methods 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 239000000017 hydrogel Substances 0.000 claims description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 7
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 6
- 239000004793 Polystyrene Substances 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 6
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 229920002223 polystyrene Polymers 0.000 claims description 6
- 229920002635 polyurethane Polymers 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 108010064470 polyaspartate Proteins 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 238000000520 microinjection Methods 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 210000003722 extracellular fluid Anatomy 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 210000002977 intracellular fluid Anatomy 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 30
- 239000000523 sample Substances 0.000 description 33
- 230000008859 change Effects 0.000 description 28
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 24
- 150000002500 ions Chemical class 0.000 description 24
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 23
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 23
- 230000004044 response Effects 0.000 description 23
- 239000002609 medium Substances 0.000 description 20
- 239000012528 membrane Substances 0.000 description 20
- 229910001415 sodium ion Inorganic materials 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 18
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 17
- 230000005284 excitation Effects 0.000 description 17
- 229910052700 potassium Inorganic materials 0.000 description 17
- 239000011591 potassium Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000003999 initiator Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000002073 fluorescence micrograph Methods 0.000 description 14
- 230000003823 potassium efflux Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 238000006116 polymerization reaction Methods 0.000 description 13
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 12
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 12
- 244000166550 Strophanthus gratus Species 0.000 description 12
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 12
- 229960004064 bumetanide Drugs 0.000 description 12
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 12
- 229960003343 ouabain Drugs 0.000 description 12
- 239000001103 potassium chloride Substances 0.000 description 12
- 235000011164 potassium chloride Nutrition 0.000 description 12
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 0 CC(C(O*NC)=O)=C Chemical compound CC(C(O*NC)=O)=C 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000006862 quantum yield reaction Methods 0.000 description 9
- 239000010453 quartz Substances 0.000 description 9
- 239000004342 Benzoyl peroxide Substances 0.000 description 8
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 235000019400 benzoyl peroxide Nutrition 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 230000004700 cellular uptake Effects 0.000 description 8
- 239000002555 ionophore Substances 0.000 description 8
- 230000000236 ionophoric effect Effects 0.000 description 8
- 210000003712 lysosome Anatomy 0.000 description 8
- 230000001868 lysosomic effect Effects 0.000 description 8
- 229910021645 metal ion Inorganic materials 0.000 description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010668 complexation reaction Methods 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 230000004941 influx Effects 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- 239000004325 lysozyme Substances 0.000 description 7
- 229960000274 lysozyme Drugs 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 6
- 208000024055 brain glioblastoma Diseases 0.000 description 6
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 6
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 6
- 102000006815 folate receptor Human genes 0.000 description 6
- 108020005243 folate receptor Proteins 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229940039009 isoproterenol Drugs 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 5
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 229910001424 calcium ion Inorganic materials 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008045 co-localization Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000295 emission spectrum Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910001425 magnesium ion Inorganic materials 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000003805 potassium influx Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- AZCYBBHXCQYWTO-UHFFFAOYSA-N 2-[(2-chloro-6-fluorophenyl)methoxy]benzaldehyde Chemical compound FC1=CC=CC(Cl)=C1COC1=CC=CC=C1C=O AZCYBBHXCQYWTO-UHFFFAOYSA-N 0.000 description 4
- YOQMJMHTHWYNIO-UHFFFAOYSA-N 4-[6-[16-[2-(2,4-dicarboxyphenyl)-5-methoxy-1-benzofuran-6-yl]-1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-yl]-5-methoxy-1-benzofuran-2-yl]benzene-1,3-dicarboxylic acid Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O YOQMJMHTHWYNIO-UHFFFAOYSA-N 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960003942 amphotericin b Drugs 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 238000004630 atomic force microscopy Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000006059 cover glass Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000000695 excitation spectrum Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012719 thermal polymerization Methods 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- FLMBQNOAWLPZPJ-UHFFFAOYSA-N 2-(3-cyano-4,5,5-trimethylfuran-2-ylidene)propanedinitrile Chemical compound CC1=C(C#N)C(=C(C#N)C#N)OC1(C)C FLMBQNOAWLPZPJ-UHFFFAOYSA-N 0.000 description 3
- WFUGQJXVXHBTEM-UHFFFAOYSA-N 2-hydroperoxy-2-(2-hydroperoxybutan-2-ylperoxy)butane Chemical compound CCC(C)(OO)OOC(C)(CC)OO WFUGQJXVXHBTEM-UHFFFAOYSA-N 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- GUCYFKSBFREPBC-UHFFFAOYSA-N [phenyl-(2,4,6-trimethylbenzoyl)phosphoryl]-(2,4,6-trimethylphenyl)methanone Chemical compound CC1=CC(C)=CC(C)=C1C(=O)P(=O)(C=1C=CC=CC=1)C(=O)C1=C(C)C=C(C)C=C1C GUCYFKSBFREPBC-UHFFFAOYSA-N 0.000 description 3
- 239000000011 acetone peroxide Substances 0.000 description 3
- 235000019401 acetone peroxide Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 3
- 239000012965 benzophenone Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 229910001447 ferric ion Inorganic materials 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000010220 ion permeability Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 2
- IQGSOFGPPDPEQW-UHFFFAOYSA-N 3-trimethylsilylpropyl prop-2-enoate Chemical compound C[Si](C)(C)CCCOC(=O)C=C IQGSOFGPPDPEQW-UHFFFAOYSA-N 0.000 description 2
- HCSXGHIWQVZBJK-UHFFFAOYSA-N 4-aminobenzo[de]isoquinoline-1,3-dione Chemical compound C1=CC=C2C(=O)NC(=O)C3=C2C1=CC=C3N HCSXGHIWQVZBJK-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000012632 fluorescent imaging Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 2
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- 238000007740 vapor deposition Methods 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- WNYJVAMZRBTOPE-YVSFHVDLSA-N 2-[(2s,5r,8r,11s)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(sulfanylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]1CC1=CC=CC=C1 WNYJVAMZRBTOPE-YVSFHVDLSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- GTELLNMUWNJXMQ-UHFFFAOYSA-N 2-ethyl-2-(hydroxymethyl)propane-1,3-diol;prop-2-enoic acid Chemical class OC(=O)C=C.OC(=O)C=C.OC(=O)C=C.CCC(CO)(CO)CO GTELLNMUWNJXMQ-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- RLTPXEAFDJVHSN-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 RLTPXEAFDJVHSN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GIPGFSVTDWZAHB-UHFFFAOYSA-N C=CCN(C(c1cccc2c1c1ccc2Br)=O)C1=O Chemical compound C=CCN(C(c1cccc2c1c1ccc2Br)=O)C1=O GIPGFSVTDWZAHB-UHFFFAOYSA-N 0.000 description 1
- FYLXYRJWIVJLNT-UHFFFAOYSA-N CC(C(N=O)=O)=C Chemical compound CC(C(N=O)=O)=C FYLXYRJWIVJLNT-UHFFFAOYSA-N 0.000 description 1
- OKPYIWASQZGASP-UHFFFAOYSA-N CC(CNC(C(C)=C)=O)O Chemical compound CC(CNC(C(C)=C)=O)O OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 description 1
- JTKUVDXPPBPIPQ-FBMGVBCBSA-N CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(/C=C/C(C(C)(CCCOCc2ccc(C=C)cc2)OC2=C(C#N)C#N)=C2C#N)cc1OCCOC Chemical compound CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(/C=C/C(C(C)(CCCOCc2ccc(C=C)cc2)OC2=C(C#N)C#N)=C2C#N)cc1OCCOC JTKUVDXPPBPIPQ-FBMGVBCBSA-N 0.000 description 1
- XTDGSVWOLJQUSR-CSKARUKUSA-N CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(/C=C/c2ccc(-c3ccc(-c4ccc(CO)[s]4)c4n[s]nc34)[s]2)cc1OCCOC Chemical compound CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(/C=C/c2ccc(-c3ccc(-c4ccc(CO)[s]4)c4n[s]nc34)[s]2)cc1OCCOC XTDGSVWOLJQUSR-CSKARUKUSA-N 0.000 description 1
- HTAFMHOBBPSTIV-UHFFFAOYSA-N CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(CCNc(cc2)c(cccc3C(N4CCNC(CCC(C(O)=O)NC(c(cc5)ccc5NCc(cnc5nc(N)n6)nc5c6O)=O)=O)=O)c3c2C4=O)cc1OCCOC Chemical compound CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(CCNc(cc2)c(cccc3C(N4CCNC(CCC(C(O)=O)NC(c(cc5)ccc5NCc(cnc5nc(N)n6)nc5c6O)=O)=O)=O)c3c2C4=O)cc1OCCOC HTAFMHOBBPSTIV-UHFFFAOYSA-N 0.000 description 1
- JZANADXQJLWLGL-UHFFFAOYSA-N CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(CCNc(cc2)c(cccc3C(N4CCOC(C(C)=C)=O)=O)c3c2C4=O)cc1OCCOC Chemical compound CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(CCNc(cc2)c(cccc3C(N4CCOC(C(C)=C)=O)=O)c3c2C4=O)cc1OCCOC JZANADXQJLWLGL-UHFFFAOYSA-N 0.000 description 1
- VDLBXRYPBVIWHW-UHFFFAOYSA-N CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(CCNc(cc2)c(cccc3C(N4CCOC(C)=O)=O)c3c2C4=O)cc1OCCOC Chemical compound CCOCCOCCN(CCOCCOCCNc(ccc(C)c1)c1OCC1)c(ccc(C)c2)c2OCCN1c1ccc(CCNc(cc2)c(cccc3C(N4CCOC(C)=O)=O)c3c2C4=O)cc1OCCOC VDLBXRYPBVIWHW-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710152055 Carbamoyl-phosphate synthase arginine-specific small chain Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- IOGAQCGZCQBXKE-UHFFFAOYSA-N Cc(cc1)cc(OCC2)c1NCCOCCOCCN(CCOCCOC)c(ccc(C)c1)c1OCCN2c1ccc(CCNc(cc2)c(cccc3C(N4CC=C)=O)c3c2C4=O)cc1OCCOC Chemical compound Cc(cc1)cc(OCC2)c1NCCOCCOCCN(CCOCCOC)c(ccc(C)c1)c1OCCN2c1ccc(CCNc(cc2)c(cccc3C(N4CC=C)=O)c3c2C4=O)cc1OCCOC IOGAQCGZCQBXKE-UHFFFAOYSA-N 0.000 description 1
- URRPDVSINPJKSC-UHFFFAOYSA-N Cc1ccc(COI)cc1 Chemical compound Cc1ccc(COI)cc1 URRPDVSINPJKSC-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SZVFWKMEQJREMC-UHFFFAOYSA-N benzene-1,3-dicarboxylic acid;1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1.OC(=O)C1=CC=CC(C(O)=O)=C1 SZVFWKMEQJREMC-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- NCMHKCKGHRPLCM-UHFFFAOYSA-N caesium(1+) Chemical compound [Cs+] NCMHKCKGHRPLCM-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
- 210000002314 coated vesicle Anatomy 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 238000001672 corrected emission spectrum Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010086416 cyclo(arginyl-glycyl-aspartyl-phenylalanyl-cysteinyl) Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- AAUNBWYUJICUKP-UHFFFAOYSA-N hypoiodite Chemical compound I[O-] AAUNBWYUJICUKP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011246 intracellular protein detection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- AZVCGYPLLBEUNV-UHFFFAOYSA-N lithium;ethanolate Chemical compound [Li+].CC[O-] AZVCGYPLLBEUNV-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940110728 nitrogen / oxygen Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000035440 response to pH Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 238000001392 ultraviolet--visible--near infrared spectroscopy Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2261/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G2261/10—Definition of the polymer structure
- C08G2261/22—Molecular weight
- C08G2261/226—Oligomers, i.e. up to 10 repeat units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2261/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G2261/30—Monomer units or repeat units incorporating structural elements in the main chain
- C08G2261/32—Monomer units or repeat units incorporating structural elements in the main chain incorporating heteroaromatic structural elements in the main chain
- C08G2261/322—Monomer units or repeat units incorporating structural elements in the main chain incorporating heteroaromatic structural elements in the main chain non-condensed
- C08G2261/3223—Monomer units or repeat units incorporating structural elements in the main chain incorporating heteroaromatic structural elements in the main chain non-condensed containing one or more sulfur atoms as the only heteroatom, e.g. thiophene
Definitions
- This disclosure relates generally to potassium ion sensors and monomers derived from such sensors.
- the disclosure also provides for polymers (e.g., random copolymers, nanoparticles, polymer thin films) and sensing films comprising polymerized monomeric potassium ion sensors. These compounds and polymers are useful for measuring intracellular and extracellular potassium ion concentrations.
- potassium ion (K + ) levels in biological samples, in vivo, in vitro, extracellular or intracellular, is essential, given the impact ion levels have on many aspects of homeostasis.
- Normal levels of potassium are important for the maintenance of heart, and nervous system function.
- Potassium ion levels that differ from a normal baseline can be associated with various disease states. For example, high levels of potassium are associated with hyperkalemia, kidney damage and diabetes, adrenal dysfunction, and trauma. Low levels of potassium, on the other hand, are associated with hypokalemia, myalgia and muscular weakness, skin related problems, and heart related problems.
- potassium ions have been measured in plasma or serum using ion-selective electrodes, which are cumbersome to use and costly to maintain. There is a need for the development of alternative methods of measuring potassium ion
- This disclosure provides new potassium ion sensors which are suitable for both intracellular and extracellular sensing.
- sensors were prepared having a double bond functional moiety, enabling the polymerization of the sensors with other commercially available monomers to create a polymeric sensor polymer, nanoparticle, or sensing film.
- the potassium ion sensors provided herein show high selectivity to sodium ion.
- the sensors exhibit no affect in performance in the presence of up to about 150 niM of sodium ions.
- dual sensors for multi-biological parameters measurements For example, a potassium ion and dissolved oxygen dual sensor.
- n is an integer from 0 to 3; and X is selected from the group consisting of:
- Non-limiting examples of a compound of formula (1) include:
- Z is selected from the group consisting of:
- n is an integer from 0 to 3; and X is selected from the group consisting of: H, OH,
- Non-limiting examples of a compound of formula (2) include:
- the compounds described above can be incorporated into a random copolymer comprising: from about 0.01 to about 10% by weight A; from about 10 to about 90% by weight B; from about 10 to about 90% by weight C; wherein A is a compound of formula (1) or (2); B is a biocompatible polymer; and C is a targeting group.
- the sum of A, B, and C is 100% by weight of the copolymer.
- a biocompatible polymer (B) can include any suitable polymer capable of polymerizing with A and C.
- a biocompatible polymer can be selected from the group consisting of: dextran, chitosan, glycol chitosan, poly-L-lysine, poly-aspartic acid, PEG and derivatives thereof, poly(amino acid)s, poly( V-isopropyl acrylamide) (PNIPAAm), poly(dimethylaminoethyl methacrylate) (PDMEM), poly(aminoethyl methacrylamide) (PAMEM), poly[(JV-2-hydroxypropyl) methacrylamide] (PHPMA), polyacrylamide, poly(2-hydroxyethyl methacrylate), poly(2-methacryloxyethyl sulfonic acid), poly(methacryloxyethyl trimethyl ammonium chloride), poly(vinyl pyridine), and poly[poly(ethylene glycol) methacrylate].
- n is independently an integer from 0 to 30.
- a targeting group (C) can be selected from the group consisting of: polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids.
- the targeting group (C) further comprises a linking group.
- the targeting group can be selected from:
- the random copolymer can further comprise from about 10 to about 100% by weight D, wherein D is a fluorescent oxygen sensor.
- D is a fluorescent oxygen sensor.
- the sum of A, B, C, and D are 100% by weight of the copolymer.
- a fluorescent oxygen sensor (D) can include a compound having the formula:
- R 7 , R 8 , R9, and R 10 are independently selected from the group consisting of: (CH 2 ) n OH, 0(CH 2 ) n OH, NH(CH 2 ) n OH, (CH 2 ) preferenceOW, 0(CH 2 ) n OW, NH(CH 2 ) conflictO , (OCH 2 CH 2 ) n OH, NH(CH 2 CH 2 0) n H, (OCH 2 CH 2 ) n OW, NH(CH 2 CH 2 0) n W;
- W is selected from the group consisting of:
- n is an integer from 0 to 10.
- D can be:
- This disclosure also provides a nanoparticle comprising polymerized monomers of one or more compounds of formula (1) and (2).
- the nanoparticle comprising polymerized monomers of one or more compounds of formula (1) and (2).
- nanoparticles can further comprise polymerized monomers of a targeting group (e.g., folic acid and cRGD), biocompatible polymer, and/or fluorescent oxygen sensor or pH sensor as described herein.
- a targeting group e.g., folic acid and cRGD
- biocompatible polymer e.g., polymethyl methacrylate
- fluorescent oxygen sensor or pH sensor e.g., folic acid and cRGD
- the monomers can be polymerized in a random copolymer.
- the diameter of the nanoparticle is about 1 nm to about 300 nm.
- the polymerized monomers of formula (1) and (2) can also be used in a polymer thin film.
- the thin film is formed on a substrate.
- a substrate e.g., organic or inorganic glass
- transparent polymer e.g., organic or inorganic glass
- transparent copolymer polymeric mixture e.g., the substrate is selected from the group consisting of plasticized or non-plasticized poly( vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof.
- the substrate is quartz glass.
- the substrate is an optic fiber bundle.
- the thickness of the polymer thin film can be from about 0.1 to about 100 ⁇ .
- sensing film comprising a substrate, as described above, covalently bound to a compound of formula (1) and/or (2).
- the compound is covalently bound to the substrate through a linker.
- the sensing film can further comprise, for example, a fluorescent oxygen sensor, a fluorescent pH sensor, or mixtures thereof.
- Intracellular sensors as described herein can also include a targeted compound having the formula:
- Z is selected from the group consisting of:
- n 0 or 1
- L is a linker
- Y is a targeting group.
- a targeted compound includes, for example, a compound having the formula:
- a targeting group can include, for example, polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids.
- the targeting group is selected from the group consisting of: folic acid, cyclo(arginine-glycine-aspartic acid) (cRGD), TAT peptides, and galactose.
- cRGD cyclo(arginine-glycine-aspartic acid)
- TAT peptides cyclo(arginine-glycine-aspartic acid)
- galactose include:
- This disclosure also provides a method of measuring potassium ion concentration in a sample.
- the method can include contacting the sample with a compound of formula (1), formula (2), or a targeted compound and measuring the fluorescence emitted by the compound.
- the sample is a fluid sample.
- a fluid sample comprising one or more cells. The potassium ion concentration can be measured in the extracellular fluid of the sample or in the intracellular fluid of the cells.
- a method of measuring potassium ion concentration in a cell comprising contacting the cell with a compound as described herein and measuring the fluorescence emitted by the compound.
- the fluorescence is measured using spectrofluorimetry.
- Any suitable cell can be used, for example, a cancer cell.
- the compound is contacted with the cell using microinjection.
- the compounds described herein can be used as discrete compounds or as a polymerized monomer in a polymer thin film or a nanoparticle.
- the compound is covalently attached to a surface.
- a method of imaging a cancer cell in a patient comprising administering to the patient an effective amount of a compound as described herein and imaging the patient.
- FIG. 1 is a schematic illustration of the preparation of a sensing film: (a) oxygen plasma treatment is used to generate active hydroxyl groups; (b) vapor deposition of thin trimethylsilylpropyl acrylate (TMPSA) layer; (c) 25 ⁇ tape used to control membrane thickness; (d) sensor solution dispensed onto modified quartz surface; (e) solution covered with a cover glass and polymerized at 80°C for 1.5 h; (f) cover glass and tape removed; film rinsed using methanol and double-distilled water; and (g) sensing membrane responding to potassium ions.
- TMPSA trimethylsilylpropyl acrylate
- FIG. 2 illustrates the potassium ion response for a sensor of Example 1 for intracellular potassium ion sensing.
- FIG. 3 illustrates the potassium ion response of a sensor of Example 2 for intracellular potassium ion sensing.
- FIG. 4 shows the fluorescent imaging of cells using a sensor of Example 1.
- FIG. 5 shows the fluorescent imaging of cells using a sensor of Example 2.
- FIG. 6 shows the extracellular potassium sensing of a sensor film having polymerized monomers of a sensor of Example 1.
- FIG. 7 shows the detection of potassium and oxygen in a dual sensor film.
- FIG. 8A shows the fluorescence change of 2(a) in HEPES buffer (pH 7.2) containing different KC1 concentrations, excited at 561 nm.
- 8B illustrates the changes of fluorescence intensities at 650 nm at different K + concentrations.
- F is the fluorescence intensity at various conditions.
- FQ is the emission intensity before the titration (with 0 mM K + ).
- 8C is a Benesi-Hildebrand plot of 2(a).
- 8D shows the fluorescence intensity change of 2(a) in the presence of various biological cations at their physiological concentrations [K + (150 mM), Na + (15 mM), Ca 2+ (2.0 mM), Mg 2+ (2.0 mM), Zn 2+ (2.0 mM), Fe 3+ (50 ⁇ ), Mn 2+ (50 ⁇ ), and Cu 2+ (50 ⁇ )] and different pH values [pH (5.0) and pH (8.0)].
- FIG. 9A illustrates the responses of 2(a) to sodium ion, potassium ion, and potassium ion at 140 mM sodium ion condition.
- 9B shows 2(a) 's responses to sodium ion, calcium ion, magnesium ion, and potassium ion.
- FIG. 10 displays confocal fluorescence images of 2(a) (4 ⁇ ) in U87MG cells co- stained with Hoechst 33342 (10 ⁇ ).
- 10(a) is a red emission from 2(a) excited at 561 nm;
- 10(b) is a blue emission from Hoechst 33342 excited at 405 nm;
- 10(c) shows an overlay of (a) and (b).
- FIG. 11 shows confocal fluorescence images of U87MG cells.
- 11 A depicts the green fluorescence image of cells stained with MitoTracker® Green.
- 11B depicts the red fluorescence image of cells stained by 2(a).
- 11C is the overlay of 11A and 11B.
- 11D is the bright field image of cells.
- FIG. 12 shows confocal fluorescence images of U87MG cells.
- 12A depicts the green fluorescence image of cells stained by SM3.
- 12B depicts the red fluorescence image of cells stained by 2(a).
- 12C is the overlay of 12A and 12B.
- 12D is the bright field image of cells.
- 12E is the chemical structure of SM3.
- FIG. 13 illustrates the time-dependent intracellular K + in U87MG cells after treatment with a mixture of nigericin, bumetanide, and ouabain for 0 min (13a and 13b), 60 minutes (13c and 13d), and 120 minutes (13e and 13f).
- FIG. 14 provides fluorescence images of 2(a) at high concentrated KC1 (20 mM) and isoproterenol (5 ⁇ M)-containing medium.
- 14a and 14c are fluorescence images.
- 14b and 14d are the fluorescence images superimposed with bright field images.
- 14a and 14b are for time of 0.
- 14c and 14d are for time of 40 minutes.
- Average fluorescence intensity increased 33% by the isoproterenol stimulation analyzed using ImageJ.
- FIG. 15 shows the time-dependent fluorescence of U87MG cells stimulated by nigericin observed under confocal fluorescence microscope.
- 15a is time of 0 before the addition of nigericin;
- 15b, 15c, 15d, 15e, 15f, and 15g are time of 1, 3, 5, 10, 15 and 25 minutes, respectively, after the addition of nigericin (20 ⁇ , final concentration) into the 20 mM KCl-containing medium;
- 15h gives the average fluorescence intensity ratios measured by ImageJ.
- 10 is the average fluorescence intensity from FIG. 15 a; I is the average fluorescence intensity at different times.
- FIG. 16 is a schematic illustration of the preparation of sensing membranes, a) oxygen plasma treatment to generate active hydroxyl groups; b) vapor deposition of thin TMSPA layer; c) 25-mm tape used to control membrane thickness; d) sensor solution dispensed onto modified quartz surface; e) solution covered with a cover glass and polymerized at 80°C for 1.5 hours; f) cover glass and tape removed; film rinsed using methanol and double-distilled water; and g) sensing membrane on quartz substrate immersed into liquid in cuvette for fluorescence measurements.
- FIG. 17A is a UV-Vis spectra of 1(a) at 0 mM and 200 mM potassium chloride (KC1) conditions.
- 17B shows the fluorescence spectral change of 1(a) in 10 mM HEPES buffer containing different C1 concentrations using an excitation wavelength at 450 nm.
- 17C provides the change of fluorescence intensity at 525 nm at different potassium ion concentrations.
- F is the fluorescence intensity at various conditions.
- F0 is the emission intensity before the titration (with 0 mM K + ).
- 17D is the Benesi-Hildebrand plot of 1(a).
- 17E shows the fluorescence intensity change of 1(a) in the presence of various biological cations at their physiological concentrations: Na + (15 mM), Ca 2+ (0.5 mM), Mg 2+ (2.5 mM), Fe 3+ (18 mM), Zn 2+ (45 mM), Mn 2+ (0.9 mM), and Cu 2+ (16 mM).
- FIG. 18A is an emission intensity change of the l(a)-conjugated PHEMA-co-PAM (F4) with KC1 in buffer.
- 18B illustrates the change of fluorescence intensity at 525 nm at different KC1 and NaCl concentrations.
- F is the fluorescence intensity at various conditions.
- F0 is the emission intensity before titration (with 0 mM K + ).
- 18C is a Benesi- Hildebrand plot of F4.
- 18D shows the influence of pH values on the fluorescence intensities at 525 nm of F4 film before and after the complexation with variable potassium ions.
- FIG. 19A shows the fluorescence intensity changes of Fl, F2, F3, and F4 titrated using KC1 in the concentration range of 0 to 10 mM.
- 19B illustrates the fluorescence intensity changes of F4, F5, F6, F7, and F8 titrated using KC1 in the concentration range of O to 10 mM.
- FIG. 20 illustrates the confocal fluorescence images of CP -A (A-D) and U87MG (E-H) cells.
- 20A and 20E depict the blue channel, showing nuclei stained with Hoechst 33342.
- 20B and 20F depict the green channel, showing the loading of 1(a) into the cells.
- 20C and 20G depict the red channel, showing lysosomes loaded with LysoTracker Red®.
- 20D is the overlay of 20 A, 20B and 20C.
- 20H is the overlay of 20E, 20F and 20G.
- FIG 21 shows the fluorescence change of cells loaded with 1(a) stimulated with ATP, amphotericin (amphoB), nigericin (Nig), and the mixture of nigericin, bumetanide, and ouabain (N+B+O).
- 21 A represents the U87MG cell line.
- 21B represents the CP-A cell line. Concentrations of the stimuli materials were: ATP (100 ⁇ ), nigericin (5 ⁇ ), amphotericin B (3.25 ⁇ ), bumetanide (10 ⁇ ), and ouabain (10 ⁇ ). 444 nm was used as the excitation wavelength and emission was measured at 538 nm using a microplate reader.
- FIG. 22 show the effect of lysozyme on K + -release from E. coli (22A) and B. subtilis (22B) visualized by F4 film.
- salt includes any ionic form of a compound and one or more counter- ionic species (cations and/or anions). Salts also include zwitterionic compounds (i.e., a molecule containing one more cationic and anionic species, e.g., zwitterionic amino acids). Counter ions present in a salt can include any cationic, anionic, or zwitterionic species.
- Exemplary anions include, but are not limited to: chloride, bromide, iodide, nitrate, sulfate, bisulfate, sulfite, bisulfite, phosphate, acid phosphate, perchl orate, chlorate, chlorite, hypochlorite, periodate, iodate, iodite, hypoiodite, carbonate, bicarbonate, isonicotinate, acetate, trichloroacetate, trifluoroacetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate,
- exemplary cations include, but are not limited to: monovalent alkali metal cations, such as lithium, sodium, potassium, and cesium, and divalent alkaline earth metals, such as beryllium, magnesium, calcium, strontium, and barium. Also included are transition metal cations, such as gold, silver, copper and zinc, as well as non-metal cations, such as ammonium salts.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from nontoxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- ACN acetonitrile
- the compounds described herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
- the reactions for preparing the compounds can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan. Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid
- LCMS chromatography-mass spectroscopy
- TLC thin layer chromatography
- potassium sensing molecules of formula (1) are provided herein.
- n is an integer from 0 to 3; and X is selected from:
- a compound of formula (1) can be prepared, for example, as shown in Scheme 1 and described in Examples 1 and 18.
- a compound of formula (1) may be prepared upon reaction of an amino compound (I) and a halo compound (II) in the presence of any reagent which would achieve formation of the compound of the N-aryl amine.
- an amine of compound (I) can be reacted with a halo compound (II) in the presence of a base.
- Suitable bases include non-nucleophilic bases such as N,N- diisopropylethylamine (DIPEA), carbonate salts (e.g., K 2 C0 3 and Cs 2 C0 3 ), triethylamine (TEA), pyridine, tributylamine, and l,8-diazabicycloundec-7-ene (DBU).
- DIPEA N,N- diisopropylethylamine
- carbonate salts e.g., K 2 C0 3 and Cs 2 C0 3
- TAA triethylamine
- pyridine tributylamine
- tributylamine l,8-diazabicycloundec-7-ene
- potassium sensing compounds of formula (2) are also provided herein.
- n is an integer from 0 to 3 (e.g., 0, 1, 2, and 3);
- X is selected from: H, OH,
- Formula (2) can include, for example,
- a compound of formula (2) can be prepared, for example, as shown in Scheme 2 and described in Examples 2 and 10.
- a compound of formula (2) may be prepared upon the condensation of an aldehyde compound (III) and a compound (IV) in the presence of any reagent which would achieve formation of targeted probes as potassium ion sensors.
- an aldehyde of compound (III) can be reacted with an activated compound (IV) in the presence of a catalyst.
- Suitable catalysts include, but are not limited to, bases such as ammonium acetate, pyridine, diisopropylethyl amine, triethyl amine, lithium ethoxide, and piperidine.
- the compounds described herein may be modified to contain targeting groups.
- Suitable targeting groups include specific and nonspecific targeting groups.
- nonspecific targeting groups can be used to enhance nonspecific uptake the compounds through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake.
- suitable nonspecific targeting groups include: glucose, sugar, dimethyl amine, diethyl amine, tetraalkyl ammonium salt, poly(dimethylaminoethyl methacrylate) (PDMEM) and poly(aminoethyl methacrylamide) (PAMEM).
- Specific targeting groups can also be used to enhance specific cellular uptake of the potassium sensors.
- suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids.
- folic acid can facilitate specific uptake of the compound by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells.
- use of a polypeptide can facilitate specific uptake by targeted cells.
- cyclic(arginine- glycine-aspartic acid) (cRGD) can target uptake by a v P3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells.
- a linker can be any suitable organic group which serves to space the sensor from the targeting group so as to maximize uptake and/or sensing.
- L and Y are covalently bound to one another.
- a linker can include one or more of a C 1-20 alkyl, C 1-2 o alkoxy, amino, and thiol moiety.
- the linker can include a pyrrole-2,5-dione.
- the linker may also include a polyethylene glycol (PEG) linker. Examples of such linkers are well known to those skilled in the art.
- the linker and targeting group are noncovalently bound to one another.
- noncovalent means for conjugation of a linker and a targeting group include, e.g., ionic bonding, hydrophobic interactions, ligand-nucleotide binding, chelating agent/metal ion pairs or specific binding pairs such as avidin/biotin, streptavidin/biotin, anti-fluorescein/fluorescein antibodies, anti-2,4-dinitrophenol (DNP)/DNP antibodies, anti-peroxidase/peroxidase, anti-digoxigenin/digoxigenin or, more generally,
- Non-limiting examples of a compound of formula (3) include:
- a compound of formula (3) can be prepared, for example, as shown in Schemes 3 and 4.
- a compound of formula (3) may be prepared upon the coupling of amine derivative of a compound of formula (1) or (2) and a targeting group in the presence of any reagent which would achieve formation of a peptide bond.
- an amine derivative of a compound of formula (1) can be directly linked to folic acid in the presence of a coupling agent.
- Suitable coupling agents include, but are not limited to, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), ⁇ , ⁇ '-dicyclohexylcarbodiimide (DCC), ArB(OH) 2 reagents, Sn[N-(TMS) 2 ] 2 , ⁇ , ⁇ '-carbonyldiimidazole, POCl 3 , T1CI 4 , molecular sieves, Lawesson's reagent, and
- the resulting derivative of the compound of formula (1) can then be reacted with a typical targeting group possessing a thio (-SH)-containing cRGD moiety, e.g., cyclo(Arg-Gly-Asp-D-Phe-Cys) or cRGDfc in DMSO or buffers (HEPES, PBS, or Tris HC1) through Michael addition reaction.
- a typical targeting group possessing a thio (-SH)-containing cRGD moiety e.g., cyclo(Arg-Gly-Asp-D-Phe-Cys) or cRGDfc in DMSO or buffers (HEPES, PBS, or Tris HC1) through Michael addition reaction.
- a polymer comprises one or more polymerized monomers of a compound of formula (2A): n is an integer from 0 to 3 (e.g., 0, 1, 2, and 3); and X is selected from:
- a polymer may be prepared by reacting two or more monomer compounds of formula (1) and/or formula (2 A) in the presence of any reagent which would achieve formation of a polymer.
- two or more monomer compounds are coupled through thermal polymerization in the presence of a thermal initiator to form a polymer.
- Suitable thermal initiators include, for example, aliphatic azo compounds such as azobisisobutyronitrile (AIBN), 4,4-azobis(4-cyanovaleric acid), and 1,1'- azobis(cyclohexanecarbonitrile) (ABCN), and organic peroxides such as benzoyl peroxide (BPO), di-t-butylperoxide (tBuOOtBu), methyl ethyl ketone peroxide, lauroyl peroxide, and acetone peroxide, and potassium persulfate.
- BPO benzoyl peroxide
- tBuOOtBu di-t-butylperoxide
- methyl ethyl ketone peroxide lauroyl peroxide
- acetone peroxide and potassium persulfate.
- two or more monomer compounds can be coupled through photopolymerization in the presence of a photo-initiator.
- Suitable photo initiators include, for example, benzophenone, 2,2- dimethoxy-2-phenylacetophenone (DMPA), 2,2-dimethoxyphenylacetophenone (Irgacure 851), and bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide (Irgacure 819).
- DMPA 2,2- dimethoxy-2-phenylacetophenone
- Irgacure 851 2,2-dimethoxyphenylacetophenone
- Irgacure 819 bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide
- the polymer may be formed into a polymer thin film.
- the polymer thin film can have a thickness ranging from about 0.1 to about 100 ⁇ (e.g., from about 0.5 to about 100 ⁇ ; from about 1 to about 100 ⁇ ; from about 10 to about 100 ⁇ ; from about 25 to about 100 ⁇ ; from about 40 to about 100 ⁇ ; from about 55 to about 100 ⁇ ; from about 65 to about 100 ⁇ ; from about 80 to about 100 ⁇ ; from about 0.1 to about 90 ⁇ ; from about 0.1 to about 75 ⁇ ; from about 0.1 to about 60 ⁇ ; from about 0.1 to about 40 ⁇ ; from about 0.1 to about 15 ⁇ ; from about 0.1 to about 5 ⁇ ; from about 0.1 to about 1 ⁇ ; from about 5 to about 75 ⁇ ; from about 10 to about 80 ⁇ ; from about 15 to about 65 ⁇ ; and from about 25 to about 50 ⁇ ).
- the polymer thin film may be formed on a substrate, for example, glass, a transparent polymer, or a transparent copolymer polymeric mixture.
- Suitable substrates include, for example, plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof.
- the substrate is an organic or inorganic glass, for example, quartz glass.
- the substrate can be an optic fiber bundle.
- a random copolymer can comprise one or more compounds (A) of formula (1) or (2A), one or more biocompatible polymers (B), and one or more targeting groups (C).
- Compound (A) can include one or more compounds of formula (1) or (2 A) as described above.
- a random copolymer can include from about 0.01 to about 10% by weight of a compound (A) (e.g., from about 0.1 to about 10%; from about 0.5 to about 10%; from about 1 to about 10%; from about 2 to about 10%; from about 4 to about 10%; from about 6 to about 10%; from about 8 to about 10%; from about 0.01 to about 8%; from about 0.
- Compound (B) can be any suitable biocompatible polymer. Suitable
- biocompatible polymers include, for example, dextran, chitosan, glycol chitosan, poly-L- lysine, poly-aspartic acid, PEG and derivatives thereof, poly(amino acid)s, poly(N- isopropyl acrylamide) (PNIPAAm), poly(dimethylamnioethyl methacrylate) (PDMEM), poly(aminoethyl methacrylamide) (PAMEM), poly[( -2-hydroxypropyl)
- a compound (B) is selected from: O o
- n is independently an integer from 0 to 30.
- one or more compound (B) monomers are incorporated into the random copolymer.
- a random copolymer can include from about 10 to about 90% by weight of a compound (B) (e.g., from about 10 to about 85%; from about 10 to about 75%; from about 10 to about 66%; from about 10 to about 52%; from about 10 to about 46%; from about 10 to about 37%; from about 10 to about 30%; from about 10 to about 26%; from about 10 to about 13%; from about 15% to about 90%; from about 26% to about 90%; from about 32% to about 90%; from about 40% to about 90%; from about 55% to about 90%; from about 64% to about 90%; from about 77% to about 90%; from about 15 to about 85%; from about 20 to about 70%; from about 25 to about 75%; from about 35 to about 66%; and from about 40 to about 60%).
- B a compound
- Suitable targeting groups (C) include specific and nonspecific targeting groups.
- nonspecific targeting groups can be used to enhance nonspecific uptake the compounds through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake.
- suitable nonspecific targeting groups include: glucose, dimethyl amine, diethyl amine, tetraalkyl ammonium salts, poly(dimethylaminoethyl methacrylate) (PDMEM) and poly(aminoethyl methacrylamide) (PAMEM).
- Specific targeting groups can also be used to enhance specific cellular uptake of the polymers.
- suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids.
- folic acid can facilitate specific uptake of the compound by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells.
- use of a polypeptide can facilitate specific uptake by targeted cells.
- cyclic(arginine- glycine-aspartic acid) (cRGD) can target uptake by v p 3 -integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells.
- a targeting group compound (C) can include:
- a random copolymer can include from about 10 to about 90% by weight of a compound (C) (e.g., from about 10 to about 85%; from about 10 to about 75%; from about 10 to about 66%; from about 10 to about 52%; from about 10 to about 46%; from about 10 to about 37%; from about 10 to about 30%; from about 10 to about 26%; from about 10 to about 13%; from about 15% to about 90%; from about 26% to about 90%; from about 32% to about 90%; from about 40% to about 90%; from about 55% to about 90%; from about 64% to about 90%; from about 77% to about 90%; from about 15 to about 85%; from about 20 to about 70%; from about 25 to about 75%; from about 35 to about 66%; and from about 40 to about 60%).
- a compound (C) e.g., from about 10 to about 85%; from about 10 to about 75%; from about 10 to about 66%; from about 10 to about 52%; from about 10 to about 46%; from about 10 to about 37%
- the random copolymer comprises a fluorescent oxygen sensor, a fluorescent pH sensor, or a combination thereof.
- a random copolymer can comprise from about 0.01 to about 10% by weight of a compound (A); from about 10 to about 90% by weight of a compound (B); from about 10 to about 90% by weight of a compound (C); and from about 0.01 to about 10% by weight of a compound (D), wherein the compounds of (A), (B), and (C) are as described above, and a compound (D) is a fluorescent oxygen sensor, a fluorescent pH sensor, or a combination thereof.
- Any suitable fluorescent oxygen sensor, or derivative thereof, capable of being polymerized can be used in the random polymers described herein.
- R l5 R 2 , R 3 , R4, R 5 , and 3 are independently selected from the group consisting of: H, F, CI, Br, I, C3 ⁇ 4, OCH 3 , OC 2 H 5 ;
- R 7 , R 8 , R 9 , and R 10 are independently selected from the group consisting of: (CH 2 ) n OH, 0(CH 2 ) n OH, NH(CH 2 ) n OH, (CH 2 ) n OW, 0(CH 2 ) n OW, NH(CH 2 ) n OW, (OC3 ⁇ 4CH 2 ) n OH,
- W is selected from:
- n is an integer from 0 to 10.
- a compound of formula (4) can include, for example:
- Any suitable fluorescent sensor, or derivative thereof, capable of being polymerized can be used in a random copolymer as described herein.
- a suitable fluorescent sensor e.g., having a vinyl moiety
- the pH sensor molecules described in U.S. Patent No. 7,390,462 which is herein incorporated by reference in its entirety.
- a random copolymer can include from about 0.01 to about 10% by weight of a compound (D) (e.g., from about 0.1 to about 10%>; from about 0.5 to about 10%; from about 1 to about 10%>; from about 2 to about 10%; from about 4 to about 10%; from about 6 to about 10%; from about 8 to about 10%>; from about 0.01 to about 8%>; from about 0.
- D a compound (D) (e.g., from about 0.1 to about 10%>; from about 0.5 to about 10%; from about 1 to about 10%>; from about 2 to about 10%; from about 4 to about 10%; from about 6 to about 10%; from about 8 to about 10%>; from about 0.01 to about 8%>; from about 0.
- D e.g., from about 0.1 to about 10%>; from about 0.5 to about 10%; from about 1 to about 10%>; from about 2 to about 10%; from about 4 to about 10%; from about 6 to about 10%; from about 8 to about 10%>; from about 0.01 to about 8%>; from about
- the sum of A, B, C, and D is 100% of the weight of the random copolymer.
- a random copolymer can be prepared through reaction of the monomers described above in the presence of any reagent which would achieve formation of a polymer.
- two or more monomer compounds are coupled through thermal polymerization in the presence of a thermal initiator to form a polymer.
- thermal initiators include, for example, aliphatic azo compounds such as
- azobisisobutyronitrile AIBN
- ABCN 1,1'- azobis(cyclohexanecarbonitrile)
- organic peroxides such as benzoyl peroxide (BPO), di-t-butylperoxide (tBuOOtBu), methyl ethyl ketone peroxide, and acetone peroxide.
- BPO benzoyl peroxide
- tBuOOtBu di-t-butylperoxide
- acetone peroxide Alternatively, two or more monomer compounds can be coupled through photopolymerization in the presence of a photo-initiator.
- Suitable photo initiators include, for example, benzophenone, 2,2-dimethoxy-2-phenylacetophenone (DMPA), 2,2-dimethoxyphenylacetophenone (Irgacure 851), and bis(2,4,6- trimethylbenzoyl)-phenylphosphineoxide (Irgacure 819).
- DMPA 2,2-dimethoxy-2-phenylacetophenone
- Irgacure 851 2,2-dimethoxyphenylacetophenone
- Irgacure 819 bis(2,4,6- trimethylbenzoyl)-phenylphosphineoxide
- all of the desired monomers can be polymerized in the presence of an initiator as described above in suitable solvents, such as DMF, DMSO, ethanol, THF, and toluene.
- suitable solvents such as DMF, DMSO, ethanol, THF, and toluene.
- the polymerization is performed under inert atmospheric conditions (e.g., N 2 or Ar).
- the resulting polymers can be collected, for example, by precipitating the polymers and further purification (e.g., by fraction and dialysis) can be performed as needed.
- the random copolymer may be formed into a polymer thin film.
- the polymer thin film can have a thickness ranging from about 0.1 to about 100 ⁇ (e.g., from about 0.5 to about 100 ⁇ ; from about 1 to about 100 ⁇ ; from about 10 to about 100 ⁇ ; from about 25 to about 100 ⁇ ; from about 40 to about 100 ⁇ ; from about 55 to about 100 ⁇ ; from about 65 to about 100 ⁇ ; from about 80 to about 100 ⁇ ; from about 0.1 to about 90 ⁇ ; from about 0.1 to about 75 ⁇ ; from about 0.1 to about 60 ⁇ ; from about 0.1 to about 40 ⁇ ; from about 0.1 to about 15 ⁇ ; from about 0.1 to about 5 ⁇ ; from about 0.1 to about 1 ⁇ ; from about 5 to about 75 ⁇ ; from about 10 to about 80 ⁇ ; from about 15 to about 65 ⁇ ; and from about 25 to about 50 ⁇ ).
- the random copolymer thin film may be formed on a substrate, for example, glass, a transparent polymer, or a transparent copolymer polymeric mixture.
- Suitable substrates include, for example, plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide,
- Suitable targeting groups include specific and nonspecific targeting groups.
- nonspecific targeting groups can be used to enhance nonspecific uptake the polymer through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake.
- suitable nonspecific targeting groups include: glucose, dimethyl amine, diethyl amine, poly(dimethylaminoethyl methacrylate) (PDMEM) and
- PAMEM poly(aminoethyl methacrylamide)
- Specific targeting groups can also be used to enhance specific cellular uptake of the polymers.
- suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids.
- folic acid can facilitate specific uptake of the compound by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human
- a polypeptide can facilitate specific uptake by targeted cells.
- cyclic(arginine- glycine-aspartic acid) cRGD
- cRGD cyclic(arginine- glycine-aspartic acid)
- a v p 3 -integrin rich cancer cell lines such as human brain glioblastoma U87-MG cells.
- nanoparticles comprising one or more polymerized monomer compounds of formula (1) or (2 A) as described above.
- a nanoparticle can be prepared as a random copolymer as described above.
- a nanoparticle, as described herein, can be prepared using methods known to those of skill in the art.
- a nanoparticle can be prepared through emulsion polymerization.
- a nanoparticle can be prepared by combining all desired monomers (e.g., monomers of formula (1) and/or formula (2A), monomers of compound (B), monomers of compound (C), and/or monomers of compound (D)) in water with a suitable surfactant and a suitable initiator.
- Suitable surfactants can include, for example, fatty acids, sodium dodecyl sulfate (SDS), and alpha olefin sulfonate.
- a surfactant can be chosen from Tween 20 and SDS.
- Suitable initiators include, for example, aliphatic azo compounds such as 4,4-azobis(4- cyanovaleric acid), azobisisobutyronitrile (AIBN) and ⁇ , ⁇ - azobis(cyclohexanecarbonitrile) (ABCN), and peroxides such as benzoyl peroxide (BPO), di-t-butylperoxide (tBuOOtBu), methyl ethyl ketone peroxide, lauroyl peroxide, acetone peroxide and hydroperoxide.
- the nanoparticle is prepared under inert atmospheric conditions (e.g., N or Ar). Nanoparticles can be purified following polymerization, for example by dialysis.
- Nanoparticles may have a diameter from about 1 nm to about 300 nm (e.g., from about 1 nm to about 250 nm, from about 1 nm to about 200 nm, from about 1 nm to about 150 nm, from about 1 nm to about 125 nm, from about 1 nm to about 100 nm, from about 1 nm to about 75 nm, from about 1 nm to about 60 nm, from about 1 nm to about 45 nm, from about 1 nm to about 25 nm, from about 1 nm to about 10 nm, from about 5 nm to about 300 nm, from about 25 nm to about 300 nm, from about 50 nm to about 300 nm, from about 75 nm to about 300 nm, from about 100 nm to about 300 nm, from about 125 nm to about 300 nm, from about 140 nm to about 400 nm, from about 200
- the nanoparticles have a diameter less than about 100 nm.
- the sizes of the nanoparticles can be characterized using, for example, dynamic light scattering (DLS), atomic force microscopy (AFM), scanning electron microscopy (SEM), or transmission electron microscopy (TEM).
- DLS dynamic light scattering
- AFM atomic force microscopy
- SEM scanning electron microscopy
- TEM transmission electron microscopy
- a nanoparticle having one or more terminal amine moieties can be
- Suitable targeting groups (C) include specific and nonspecific targeting groups.
- nonspecific targeting groups can be used to enhance nonspecific uptake the compounds through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake.
- suitable nonspecific targeting groups include:
- Specific targeting groups can also be used to enhance specific cellular uptake of the nanoparticles.
- suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids.
- folic acid can facilitate specific uptake of the nanoparticles by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human
- nasopharyngeal epidermal carcinoma KB cells use of a polypeptide can facilitate specific uptake by targeted cells.
- cyclic(arginine- glycine-aspartic acid) cRGD
- cRGD cyclic(arginine- glycine-aspartic acid)
- a v p3-integrin rich cancer cell lines such as human brain glioblastoma U87-MG cells.
- sensing films comprising a substrate covalently bound to a compound of formula (1) or (2A).
- the substrate is covalently bound to the compound through a linker.
- a linker can be any suitable organic group which serves to space the substrate from the compound so as to enable the sensing film to be chemically immobilized on the substrates, maximize sensing sensitivity or signal intensity.
- a linker can include one or more of a C 1-20 alkyl, C ⁇ o alkoxy, amino, silane, maleimide, and thiol moiety.
- the linker may also include a polyethylene glycol (PEG) linker.
- the linker can include a vinyl, acrylate, or methacrylate moiety to facilitate polymerization of the compound of formula (1) or (2 A) to the linker. Examples of such linkers are well known to those skilled in the art.
- a substrate can be any substrate suitable for the preparation of sensing membranes.
- a substrate can include glass, a transparent polymer, or a transparent copolymer polymeric mixture.
- Suitable substrates also include, for example, plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials,
- the substrate is an organic or inorganic glass, for example, quartz glass.
- the substrate can be an optic fiber bundle.
- a crosslinker comprises at least two of the following: a vinyl, acrylate, methacrylate, acrylamide, and methacrylamide functional group.
- the crosslinkers can include poly(ethylene glycol) dimethacrylate, ethoxylated trimethylolpropane triacrylate (SR454), and bio(ethylamine)acryamide.
- the sensors were copolymerized into suitable matrices.
- suitable matrices for example, an ion permeable matrix such as poly(2-hydroxyethyl methacrylate), poly(acrylamide), poly[(ethylene glycol) methacrylate] can be used.
- a sensing film as described herein can be prepared, for example, as shown in FIGs. 1 and 16.
- the sensing film can be prepared by reacting a compound of formula (1) or (2A) with an initiator in the presence of matrix monomers such as the 2- hydroxyethyl methacrylate, acrylamide and a crosslinker in a solvent (e.g., DMF), or a functionalized substrate (e.g., an acrylate-moiety functionalized quartz glass).
- matrix monomers such as the 2- hydroxyethyl methacrylate, acrylamide and a crosslinker
- a solvent e.g., DMF
- a functionalized substrate e.g., an acrylate-moiety functionalized quartz glass
- Polymerization can be carried out under inert atmosphere and at elevated temperature.
- the sensing film prepared can then be purified as needed to remove any non-polymerized monomers or residual solvent. Fluorescence Assays
- Fluorescence of a sensor may be detected by any suitable fluorescence detection device.
- Such devices are typically comprised of a light source for excitation of the fluorophore and a sensor for detecting emitted light.
- fluorescence detection devices typically contain a means for controlling the wavelength of the excitation light and a means for controlling the wavelength of light detected by the sensor (e.g., filters, diffraction gratings, and dichroic mirrors).
- suitable devices include fluorimeters, spectrofluorimeters and fluorescence microscopes. Many such devices are commercially available from companies such as Hitachi, Nikon, Molecular Dynamics or Zeiss.
- the device is coupled to a signal amplifier and a computer for data processing.
- assays using a sensor as provided herein involve contacting a sample with such a sensor and measuring fluorescence.
- methods are provided for measuring the concentration of potassium ions in a sample.
- concentration of oxygen and hydronium ions (pH) may also be determined.
- the presence of an analyte (e.g., potassium ion, oxygen, or hydronium ion) that interacts with the sensor may alter fluorescence of the sensor in many different ways. Essentially any change in fluorescence caused by the analyte, typically the potassium ion, may be used to determine the presence of the ion and, optionally, the concentration of the ion in the sample.
- the change may take one or more of several forms, including a change in excitation or emission spectra, or a change in the intensity of the fluorescence and/or quantum yield. These changes may be either in the positive or negative direction and may be of a range of magnitudes, which preferably will be detectable as described below.
- the excitation spectrum is the wavelengths of light capable of causing the sensor to fluoresce.
- different wavelengths of light are tested sequentially for their abilities to excite the sample.
- emitted light is measured. Emitted light may be measured across an interval of wavelengths (for example, from 450 to 700 nm) or emitted light may be measured as a total of all light with wavelengths above a certain threshold (for example, wavelengths greater than 500 nm).
- a profile is produced of the emitted light produced in response to each tested excitation wavelength, and the point of maximum emitted light can be referred to as the maximum excitation wavelength.
- a change in this maximum excitation wavelength, or a change in the shape of the profile caused by ion in a sample may be used as the basis for determining the presence, and optionally, the concentration of ion in the sample.
- the emission spectrum may be determined by examining the spectra of emitted light in response to excitation with a particular wavelength (or interval of wavelengths). A profile of emissions at different wavelengths is created and the wavelength at which emission is maximal is called the maximum emission wavelength. Changes in the maximum emission wavelength, emission intensity, or the shape of the profile that are caused by the presence of an in a sample may be used to determine the presence or concentration of the ion in the sample. Changes in excitation or emission spectra may be measured as ratios of two wavelengths. A range of changes are possible, from about a few nm to 5, 10, 15, 25, 50, 75, 100, or more nm.
- Quantum yield may be obtained by comparison of the integrated area of the corrected emission spectrum of the sample with that of a reference solution.
- a preferred reference solution is a solution of fluorescein in 0.1 N NaOH, quantum efficiency 0.95. The concentration of the reference is adjusted to match the absorbance of the test sample.
- the quantum yields may be calculated using equations known to those of skill in the art.
- a change in quantum yield caused by an ion may be used as the basis for detecting the presence of the ion in a sample and may optionally be used to determine the concentration of the ion.
- a range of changes are possible.
- the difference in the quantum yield for a subject sensor in the presence of a ion may be about 10%, 25%, 50%, 75% the quantum yield, or it may be 2, 3, 5, 10, 100, 200, 1000, or 10000 times greater or more. The same values may be used to describe changes observed in intensity in such the subject assays.
- the fluorescence may be used to determine the presence or concentration of one or more such ion-competing compounds in a sample.
- potassium ion sensing sodium ions are a common interfering ion for fluorescence measurements.
- the fluorescent sensing moieties provided herein, however, are largely unaffected by changes in pH and sodium ion concentration.
- the presence of potassium ion in a sample is detected by contacting the sample with a sensor as described herein.
- the fluorescence of the solution is then determined using one of the above-described devices, for example, a
- the fluorescence of the solution may be compared against a set of standard solutions containing known quantities of the ion, e.g., potassium.
- Comparison to standards may be used to calculate the concentration of the ion in the sample.
- the analyte may be any described above (e.g., potassium ion, oxygen, or hydronium ion).
- concentration of the analyte may change over time and the fluorescent signal of the sensor may serve to monitor those changes.
- the particular form of the potassium ion that interacts with the sensor may be produced or consumed by a reaction occurring in the solution, in which case the fluorescence signal may be used to monitor reaction kinetics.
- a sensor as provided herein can be used to determine and quantitate the antibacterial qualities of a compound. Antibacterial compounds can stimulate a K+ efflux from the bacteria, which can be monitored through time dependent fluorescence intensity changes of the sensor.
- a solution of a particular bacterium can be prepared in a medium (e.g., NaCl) in the presence of one or more sensing compounds.
- a candidate antibacterial compound Upon addition of a candidate antibacterial compound, any K+ releasing from the bacteria into solution can be monitored through an increase in the fluorescence intensity of the sensor. The rate of K+ efflux can be used to observe and quantitate the antibacterial properties of the compound against the particular bacterium. See, for example, Example 23.
- the sample is a biological fluid, lysate, homogenate or extract.
- the sample may contain one or more cells. Samples may have a pH of about 5, 6, 7, 8, 9, 10, 11, 12, or higher.
- the presence of an ion in a biological sample may be determined using a fluorescence microscope and one or more sensors described herein.
- the biological sample is contacted with the sensor and fluorescence is visualized using appropriate magnification, excitation wavelengths, and emission wavelengths.
- the sample may be contacted with multiple sensors simultaneously.
- the multiple sensors differ in their emission and/or excitation wavelengths.
- Biological samples may include bacterial or eukaryotic cells, tissue samples, lysates, or fluids from a living organism.
- the eukaryotic cells are cancer cells, for example, folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells, or a v p 3 -integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells.
- Detection of an ion in a cell may include detection of the ion in subcellular or extracellular compartments or organelles.
- subcellular organelles and compartments include: Golgi networks and vesicles, pre-synaptic vesicles, lysosomes, vacuoles, nuclei, chromatin, mitochondria, chloroplasts, endoplasmic reticulum, coated vesicles (including clathrin coated vesicles), caveolae, periplasmic space and extracellular matrices.
- the sensors used for intracellular detection can include a compound of formula (1), (2A) or (3), polymers, random copolymers, or nanoparticles as described herein. Such intracellular measurements may be obtained by contacting the cell with a sensor as described above. In some embodiments, the sensor is contacted with the cell using microinjection.
- Target compounds, polymers, and nanoparticles as described above may also be used to image a targeted cell in a patient.
- the patient can be administered an effective amount of the desired targeted compound and imaged using suitable fluorescence techniques.
- Any cancer cell can be imaged if an appropriate targeting moiety is used.
- folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells can be imaged using a folic acid targeting group, or a v p 3 -integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells can be imaged using a cRGD targeting group.
- Suitable fluorescence techniques for in vivo imaging can include a Xeneogen IVIS-200 System. Typically, such imaging will involve excitation of the fluorescent sensor using wavelengths of about 488 nm or longer to provide an emission spectrum in the green and red windows.
- Detection of an ion in a fluid sample for example, in the extracellular matrix of a biological sample, can be performed using an extracellular sensor such as those described above, or a compound of formula (2), such as:
- compositions When employed as pharmaceuticals, the compounds, polymers, and nanoparticles described herein can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- compositions which contain, as the active ingredient, a compound, polymer, or nanoparticle of the invention or a
- an active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If an active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If an active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
- the compounds, polymers, and nanoparticles described herein may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
- Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- the compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the active ingredient.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- the compositions contain from about 5 to about 50 mg of the active ingredient.
- this embodies compositions containing about 5 to about 10, about 10 to about 15, about 15 to about 20, about 20 to about 25, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 40 to about 45, or about 45 to about 50 mg of the active ingredient.
- the compositions contain from about 50 to about 500 mg of the active ingredient.
- this embodies compositions containing about 50 to about 100, about 100 to about 150, about 150 to about 200, about 200 to about 250, about 250 to about 300, about 350 to about 400, or about 450 to about 500 mg of the active ingredient.
- the compositions contain from about 500 to about 1000 mg of the active ingredient.
- the compositions contain from about 500 to about 1000 mg of the active ingredient.
- One having ordinary skill in the art will appreciate that this embodies compositions containing about 500 to about 550, about 550 to about 600, about 600 to about 650, about 650 to about 700, about 700 to about 750, about 750 to about 800, about 800 to about 850, about 850 to about 900, about 900 to about 950, or about 950 to about 1000 mg of the active ingredient.
- the active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the area being imaged as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
- compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the compound preparations typically will be between 3 and 11 , more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
- TAC-NH2 amino-substituted triazacryptand ionophore
- TAC-CHO acetate- substituted triazacryptand ionophore
- compound 1 N-2-propenyl-4-bromo-naphthalimide
- TCF 2-dicyanomethylene-3-cyano-4,5,5-trimethyl-2,5-dihydrofuran
- Lysosensor SM3 was prepared according to our published procedure (Tian, Y. et al., Biomaterials 2010, 31, 7411-7422). HEMA, AM, METAC, trimethylsilylpropyl acrylate (TMSPA),
- azobisisobutyronitrile AIBN
- DIPEA ⁇ , ⁇ -diisopropylethylamine
- NMP N-methyl-2- pyrrolidone
- amphotericin KC1, NaCl, CaCl 2 , MgCl 2 , FeCl 3 , ZnCl 2 , CuCl 2 , 4-(2- hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES), nigericin, bumetanide, and ouabain were purchased from Sigma-Aldrich (St. Louis, MO).
- Hoechst 33342, PBFI, and MitroTracker ® Green FM were ordered from Invitrogen (Carlsbad, CA).
- a Shimadzu RF-5301 spetrofluorophotometer was used for fluorescence measurements.
- Example 2 A method of synthesis of a compound of formula (2):
- the desired monomers including monomeric compounds of formula (1) and (2A), monomers of compounds (D), monomers of compound (B, and monomers of compound (C) with controlled molar or weight ratios) and initiator (e.g., AIBN) will be dissolved in suitable solvent (e.g., DMF, DMSO, ethanol, or water).
- suitable solvent e.g., DMF, DMSO, ethanol, or water.
- the mixture will be degassed a few times and filled with nitrogen.
- the polymerization will be carried out under the nitrogen condition and at 65 °C for a time sufficient to complete polymerization (e.g., 24 hours). After polymerization, the polymer can be precipitated from the reaction mixture.
- the polymers can be further purified using dialysis approach.
- the desired monomers (including monomeric compounds of formula (1) and
- (2A) monomers of compounds (D), monomers of compound (B, and monomers of compound (C) with controlled molar or weight ratios) and initiator (e.g., AIBN) will be suspended in water with a suitable surfactant (e.g., Tween 20 or SDS).
- a suitable surfactant e.g., Tween 20 or SDS.
- the polymerization will be carried out under the nitrogen condition and at 65 °C for a time sufficient to complete the polymerization (e.g., 24 hours).
- the formed nanoparticles will be purified using dialysis.
- the sizes of the nanoparticles will be characterized using dynamic light scattering (DLS) atomic force microscopy (AFM), scanning electron microscopy (SEM), or transmission electron microscopy (TEM).
- DLS dynamic light scattering
- AFM atomic force microscopy
- SEM scanning electron microscopy
- TEM transmission electron microscopy
- Sensing films can be prepared either through thermal polymerization (using 4,4- azobis(4-cyanovaleric acid), azobisisobutyronitrile (AIBN) or benzoyl peroxide (BPO) as the thermal initiators) or using a photoinitiator, such as Benzophenone, Irgacure 851 (2,2- dimethoxyphenylacetophenone), or Irgacure 819 (bis(2,4,6-trimethylbenzoyl)- phenylphosphineoxide).
- a sensor as prepared in Example 1, a thermal polymerization initiator, and comonomers with a crosslinker for the matrix were dissolved in ⁇ , ⁇ '- dimethyl formamide (DMF). The DMF solution was added onto an acrylate-moiety functionalized quartz glass and the solution was covered with a clean cover slip
- Polymerization was carried out under nitrogen at 80 °C for 1.5 hours.
- the quartz glass with a polymer film was removed from the oven, and the tape and cover slip were removed.
- the uniform polymer film on the quartz glass was then washed three times with methanol, followed by three times with double-distilled water, to remove any non- polymerized monomers and the residual DMF.
- the films were dried and stored in the dark at room temperature.
- This method was also used to prepare a dual sensing film for potassium ion and oxygen sensing.
- the above procedure was followed, except two sensing monomers, the potassium monomer from Example 1 and an oxygen monomer having the structure:
- Example 6 Measuring sensor response in aqueous solution.
- a solution of a sensor of Example 1 and Example 2 was prepared at a
- Example 1 concentration of 5 ⁇ /L in HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid) buffer was titrated with various potassium ion concentrations.
- Sensors of Example 1 were excited at 450 nm to generate its green emission (FIG. 2), and collected from 470 nm to 650 nm with a maximum at 520 nm.
- Sensors of Example 2 were excited at 488 nm to generate its red emission (FIG. 3) collected from 550 nm to 750 nm with a maximum at 650 nm. The response for each sensor is shown in FIGs. 2 and 3.
- the potassium ion sensing film prepared in Example 5 was immersed in a buffer and the emissions of the film were monitored upon the change of potassium ion concentration. Sensors were excited at 450 nm and typical emissions were collected from 470 nm to 650 nm for the green emission. The response of the film to varied
- concentrations of potassium, sodium, and pH is shown in FIG. 6.
- the sensing film is specific for potassium and measures little interference from sodium, lithium, and cesium ion also present in solution.
- the sensing film is unaffected by changes in pH.
- Example 9 Measuring oxygen and potassium ion response in a dual sensing film
- a dual potassium and oxygen sensing film was prepared as described in Example 5.
- the sensing film was placed diagonally into quartz cuvettes containing buffers or cell culture medium.
- the sensors were excited at 440 nm to generate the green emission from the potassium ion sensor and the red emission of the oxygen sensor.
- concentration was adjusted by bubbling a nitrogen/oxygen gas mixture into the liquid contained in the cuvette. After the saturation of the liquid using the gas mixture with defined oxygen concentration, the emission spectra were taken. Potassium ion concentration in the solution was adjusted by tuning the concentrations of potassium chloride to measure the responses of the dual sensor film.
- Example 10 A method of synthesis of a compound of Formula (2): (2a)
- TAC-CHO compound III; 100 mg, 138.5 ⁇
- TCF 2-dicyanomethylene-3-cyano-4,5,5-trimethyl-2,5-dihydrofuran
- TCF compound IV
- NaOH 2 mg
- the deep violet solution was extracted with dichloromethane from water, and the organic layer was dried with MgS0 4 .
- the crude product was purified by column chromatography over silica gel to get a dark-purple solid (62 mg, yield: 49.6%).
- a x and A s are the absorbance of the standards and the measured samples at the excitation wavelength, respectively.
- I x and 7 S are the integrated emission intensities of standards and the samples, respectively.
- n t and n s are the refractive indices of the corresponding solvents present in the solutions, respectively. The experimental error was approximately 10%.
- FIG. 8 Data for 2(a) is shown in FIG. 8. Because of the strong derealization of electrons in the push-pull fluorophore in 2(a), the complex ability of the nitrogen atom of the aniline group, a component of the ligand for the potassium ion, decreased significantly. Such a decrease may result in a blunted binding ability of the whole ligand in the compound and decreased sensitivity of the intramolecular charge transfer (ICT) to the complexation with K + to achieve a K4 of around one-tenth mole level.
- ICT intramolecular charge transfer
- 2(a) is constructed using strong electron-donating (aniline) and electron- withdrawing (TCF) groups, yielding an absorption maximum at 560 nm.
- the extinction coefficient ( ⁇ ) at 560 nm is 3.84 10 4 M _1 cm " .
- 2(a) displays weak fluorescence in its free form with a quantum yield ( ⁇ ) of 0.11%.
- K + the fluorescence intensity of 2(a) increases by ca. 4 and 50 fold at K + concentrations of 140 mM and 1400 mM (FIG 8A and 8B), respectively, resulting in corresponding ⁇ of 0.52% and 5.6%.
- Kj was determined by the Benesi-Hildebrand equation:
- FQ is the integrated fluorescence intensity of a free sensor
- F is the observed integrated fluorescence intensity
- -Fcompiex is the emission of the ligand-metal ion complex
- [M] is the metal ion concentration.
- FQ/(FO - F) is plotted against 1/[M]
- the binding constant is given by the ratio intercept/slope.
- Curve fitting of 2(a) fluorescence intensity against the reciprocal of the K + concentration (1/[K + ]) yields a linear fit (FIG. 8C), where the Kd was estimated to be 88 mM.
- the linear fit evidences a 1 : 1 complexation behavior.
- Example 12 Cell culture for imaging and subcellular distribution of the sensor U87MG cells (American Type Culture Collection, ATCC, Manassas, VA) were cultured in Eagle's minimum essential medium (EMEM) supplemented with 10% fetal bovine serum, 100 ⁇ /mL penicillin, 2 mM L-glutamine (Sigma- Aldrich), and incubated at 37 °C in 5% C0 2 atmosphere. Cells were then seeded onto 96 well plates at 10,000 cells per well, and incubated for 1 day at 37 °C. CP-A cells (kindly provided by Dr. Brian J. Reid at Fred Hutchison Cancer Research Center, Seattle, WA) were cultured in
- Keratinocyte-serum free medium (Invitrogen, Carlsbad, CA) supplemented with Bovine Pituitary Extract (BPE) and human recombinant Epidermal Growth Factor (rEGF, Invitrogen) at 37 °C in a 5% C0 2 atmosphere.
- BPE Bovine Pituitary Extract
- rEGF human recombinant Epidermal Growth Factor
- the cells were treated in the same manner as the Hoechst staining method, but with a MitoTracker® Green FM in DMSO solution.
- Lysosensor SM3 was used. Again the cells were treated using the previously stated protocol while using a SM3 in DMSO solution.
- the resulting concentrations of Hoechst 33342, MitoTracker® Green FM, and Lysosensor SM3 in the cell medium were 10 ⁇ , 50 nM, and 2 ⁇ respectively.
- Hoechst 33342 was excited at 405 nm and its blue emission was collected using a 450/35 nm filter set.
- Sensor (1(a)) was excited at 440 nm and the green emission was collected using a 515/30 nm filter set.
- Sensor (2(a)) was excited at 561 nm and its red emission was collected using a 605/75 nm filter set.
- Lysosensor SM3 was excited at 405 nm and its green emission was collected using a 515/30 nm filter set.
- MitoTracker ® Green FM was excited at 488 nm and its green emission was collected using a 515/30 nm filter set.
- Cytotoxicity of 2(a) to human glioblastoma U87MG cells was studied using Trypan blue staining.
- 2(a) can also be used to monitor K + influx through stimuli.
- U87MG cells were seeded onto 96 well plates at 10,000 cells per well in 100 iL medium overnight at 37°C. On the following day, the cells were internalized with 2(a) (4 ⁇ ) for 10 min at 37°C.
- the influx stimulator (isoproterenol in KCl-containing PBS buffer) was added. Final concentrations of the added isoproterenol and KCl in the cell culture medium were 5 ⁇ and 20 mM, respectively. Fluorescence in cells was visualized by Nikon Eclipse
- Isoproterenol was reported to be a potassium ion influx stimulator by stimulating cyclic adenosine monophosphate (cAMP) generation, which associates with physiology change in K + transport.
- cAMP cyclic adenosine monophosphate
- Thin films were prepared according to our published protocols (Tian Y. et al., Biomaterials 2010; 31 :7411-7422; and Tian Y. et al, Chem Mater 2010; 22:2069-2078).
- a schematic drawing of the film preparation is given in FIG. 16.
- F4 film is described as a typical example.
- the components of other films are given in Table 1.
- F8 PHEMA:PAM:PMESA 80:15:20
- Each film contains a 5%-weight percent SR454 crosslinker.
- the sensitivity of the sensing films to + was at the 0 and 10 mM KCl conditions for comparison because this range is usually enough for extracellular K + sensing.
- F 0 is the fluorescence intensity before the titration using KCl.
- F is the fluorescence intensity at 10 mM KCl.
- TMSPA-modified quartz glass 1 mg was added onto the surface of the TMSPA-modified quartz glass and covered with a clean but untreated cover slip to make a sandwich structure.
- TMSPA to modify the quartz glass was to enable the sensors and matrices to be chemically grafted onto a quartz substrate (Tian Y, et al., Chem Mater 2010; 22:2069-2078). The thickness was controlled using 25 ⁇ Kapton tape (DuPont, Wilmington, DE).
- the sandwich set-up was placed into a vacuum oven, which was then evacuated and refilled with nitrogen three times. Polymerization was carried out under nitrogen at 80 °C for 1.5 h in the oven.
- the quartz glasses with polymer membranes were removed from the oven, then the Kapton tape and non-surface modified glass was removed from the polymerized membrane surface.
- the polymerized membranes on the quartz glasses were washed three times with methanol to remove any remaining non-polymerized monomers and residual DMF.
- the films were dried and stored away from light at room temperature.
- the sensing films were stable in water for at least 3 months without any leaching of the sensing moieties or change hi sensing performance.
- E. coli JM 109 and B. subtilis 168 were cultured overnight in LB medium
- E. coli and B. subtilis in culture were estimated by measuring the optical density at 600 nm (OD 60 o)- OD 60 o value of 1 indicated a concentration of 5.0 ⁇ 10 cfu/mL. After the microorganism density was determined, bacterial cells were collected by centrifuge at 2000 x g for 20 minutes at room temperature. Then appropriate densities of bacteria were made using fresh buffer (150 mM NaCl, pH 7.4) to achieve the desired initial concentrations for experiments.
- the F4 film (Example 16) was placed diagonally into quartz cuvettes with 2 mL of bacteria suspension at different densities. Potassium release from the bacteria was stimulated by adding 100 of 20 mg/mL lysozyme. Emission measurements were taken every 5 min at the sensor's peak emission (525 nm) using an excitation wavelength of 450 nm. The potassium ion concentration was calculated from the measured fluorescence ratio (F/F Q ).
- Example 18 Sensing performance of 1(a) in buffer.
- FIGs. 17A and 17B show the UV-Vis and emission spectral changes upon the interaction of 1(a) with potassium chloride (KC1) in 10 mM HEPES buffer (pH 7.4).
- KC1 potassium chloride
- the absorption spectra before and after interaction with K + did not change, while emission intensities increased with increasing K + concentrations. This fluorescence change was attributed to photo-induced electron transfer.
- the lone electron pairs of the amino groups in the triazacryptand ligand quench the emission of the fluorophore of the amino- naphthalimide through PET. After interaction with K + , the lone electron pairs of the ligand were occupied due to the formation of the ligand-K + complex.
- Na + is usually an interference ion to K + for the typical K + probes including PBFI, CD 18, CI 8, and MCC.
- U87MG and CP-A cells were seeded onto 96 well plates at 10,000 cells per well and maintained in 100 iL medium overnight. The following day, the cells were loaded with 1(a) (2 ⁇ ) for 20 min, then the excess 1(a) was removed by washing with medium. The test substances were added and the experiment was terminated after 2.5 h by washing the cells with physiological NaCl solution.
- a microplate reader (Molecular Device, Downingtown, PA) was used to read the fluorescence intensities from the intracellular 1(a). 444 nm was used to excite the sensor and the emission was measured at 538 rrm. The measured fluorescence intensities were corrected with background fluorescence. Each experiment was repeated in triplicate.
- Example 20 Sensing performances of 1(a) in the membranes of Fl to F8.
- FIG. 18A shows the emission change upon titration with KC1. Its corresponding fluorescence intensities at 525 nm were given in FIG. 18B. The sensing response to Na + was also given in FIG. 18B, showing the high selectivity of K + to Na + . This trend is in accordance with that of pure 1(a) in buffer. However, the sensitivity of this sensing film F4 is better than that of pure 1(a), which may possibly be due to the fact that this sensing film can be swollen by water, resulting in a better interaction of the sensing moiety in the PHEMA-co-PAM hydrogel with K + . Curve fitting of the fluorescence intensity of F4 against the reciprocal of K + concentration (1/[K + ]) using the Benesi-Hildebrand equation 1 gives a linear fit (FIG. 18C). This suggests the
- FIG. 18D plots the pH dependent fluorescence changes at different pH values. Results showed that this sensing membrane before the complexation with K + had no response to pH from 6 to 8. After the complexation with the K + , the sensing membrane did not respond to pH from 5 to 8. These results are in accordance with other K + sensors derived from the triazacryptand ligand. These results showed our K + sensors are minimally influenced by biological pH values.
- FIG. 19 gives the comparison of the responses of the eight thin films to K + .
- the sensing membrane made of PAM matrix (Fl) did not response to K + , indicating its poor K + permeability.
- Sensing membrane F2 made of PHEMA has better response to K + than that of Fl.
- the two films of F3 and F4 show much better sensitivity than F2, indicating the chemical composition of the PFTEMA-c -PAM improves K + permeability. It is known that PHEMA can have good swelling properties and ion permeability.
- the composite materials can increase the swelling degree (W ⁇ ) and therefore increase the range of pore sizes and size distribution in the hydrogel film. To our knowledge, this is the first study of matrix influence on potassium ion sensitivity of a K + probe
- FIG. 20 shows the confocal fluorescence images of 1(a).
- 1(a) can internalize with cells within a short time, as few as 10 minutes.
- a 1(a) concentration of 0.5 ⁇ in cell culture medium was able to stain cells, but the signal was weak.
- a sensor concentration of 2 ⁇ was used for intracellular study. Bright green fluorescence was not uniform throughout the cells, implying the nonuniform K + distribution of the intracellular K + in the cytoplasm area.
- Cytotoxicity of the sensor 1(a) to cells was studied using Trypan blue staining. After 30 minutes internalization of the sensor with cells, more than 97% cells were viable, showing the non-cytotoxicity of 1(a) to the two cell lines under our experimental conditions.
- Example 22 Stimuli responsive change of the intracellular K* level.
- 1(a) was demonstrated to be a new candidate for the monitoring of intracellular potassium ion balance.
- Example 23 Application of the K + sensing films for studying antimicrobial reagents.
- F4 film was used for both gram positive (i.e. B. subtilis) and negative (i.e. E. coli) bacteria and lysozyme was used as a model drug to stimulate K + efflux from the organisms.
- the bacteria were cultured at 37 °C overnight, centrifiiged, and washed three times with potassium-free buffer with 150 mM NaCl at pH of 7.4. The washed organisms were resuspended in 2 mL of the potassium-free buffer in quartz cuvettes at a
- FIG. 22 plots the time and bacterial concentration- dependent K + concentration changes measured by using F4 film.
- E. coli + efflux increased slowly over time; while for B. subtilis, K + efflux was very fast, within the first 10 minutes, and then very slow within the rest of time course. The difference between E. coli and B.
- subtilis is due to the antibacterial properties and action mode of lysozyme, which is more facile and faster in B. subtilis (gram-positive bacteria) compared to E. coli (gram-negative bacteria).
- the bactericidal properties of lysozyme are primarily ascribed to its N-acetylmuramoyl hydrolase enzymatic activity, resulting in peptidoglycan hydrolysis and cell lysis.
- Gram-negative bacteria are relatively insensitive to lysozyme by the virtue of their outer membrane that acts as a physical barrier preventing access of the enzyme.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
This disclosure relates generally to potassium ion sensors and monomers derived from such sensors. The disclosure also provides for polymers (e.g., random copolymers, nanoparticles, polymer thin films, and sensors) having polymerized monomeric potassium ion sensors as described herein. These compounds and polymers are useful for measuring intracellular and extracellular potassium ion concentrations.
Description
Fluorescent Potassium Ion Sensors
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial No.
61/442,518, filed on February 14, 2011, which is incorporated by reference in its entirety herein.
GRANT INFORMATION
This invention was made with government support under 5P50 HG002360 awarded by the National Institute of Health. The government has certain rights in the invention.
TECHNICAL FIELD
This disclosure relates generally to potassium ion sensors and monomers derived from such sensors. The disclosure also provides for polymers (e.g., random copolymers, nanoparticles, polymer thin films) and sensing films comprising polymerized monomeric potassium ion sensors. These compounds and polymers are useful for measuring intracellular and extracellular potassium ion concentrations.
BACKGROUND
The accurate measurement of potassium ion (K+) levels in biological samples, in vivo, in vitro, extracellular or intracellular, is essential, given the impact ion levels have on many aspects of homeostasis. Normal levels of potassium are important for the maintenance of heart, and nervous system function. Potassium ion levels that differ from a normal baseline can be associated with various disease states. For example, high levels of potassium are associated with hyperkalemia, kidney damage and diabetes, adrenal dysfunction, and trauma. Low levels of potassium, on the other hand, are associated with hypokalemia, myalgia and muscular weakness, skin related problems, and heart related problems. Traditionally, potassium ions have been measured in plasma or serum using ion-selective electrodes, which are cumbersome to use and costly to maintain. There is a need for the development of alternative methods of measuring potassium ion
concentration in a variety of sample mediums.
SUMMARY
This disclosure provides new potassium ion sensors which are suitable for both intracellular and extracellular sensing. For extracellular sensing, for example, sensors were prepared having a double bond functional moiety, enabling the polymerization of the sensors with other commercially available monomers to create a polymeric sensor polymer, nanoparticle, or sensing film. In addition, the potassium ion sensors provided herein show high selectivity to sodium ion. For example, the sensors exhibit no affect in performance in the presence of up to about 150 niM of sodium ions. Further provided herein are dual sensors for multi-biological parameters measurements. For example, a potassium ion and dissolved oxygen dual sensor.
Provided herein is a compound of formula (1):
or a salt form thereof, wherein: m is 0 or 1; n is an integer from 0 to 3; and X is selected from the group consisting of:
X
or a salt form thereof.
Also provided herein is a compound of formula (2):
Non-limiting examples of a compound of formula (2) include:
10
11
or a salt form thereof.
The compounds described above can be incorporated into a random copolymer comprising: from about 0.01 to about 10% by weight A; from about 10 to about 90% by weight B; from about 10 to about 90% by weight C; wherein A is a compound of formula (1) or (2); B is a biocompatible polymer; and C is a targeting group. In some
embodiments, the sum of A, B, and C is 100% by weight of the copolymer.
A biocompatible polymer (B) can include any suitable polymer capable of polymerizing with A and C. For example, a biocompatible polymer can be selected from the group consisting of: dextran, chitosan, glycol chitosan, poly-L-lysine, poly-aspartic acid, PEG and derivatives thereof, poly(amino acid)s, poly( V-isopropyl acrylamide) (PNIPAAm), poly(dimethylaminoethyl methacrylate) (PDMEM), poly(aminoethyl methacrylamide) (PAMEM), poly[(JV-2-hydroxypropyl) methacrylamide] (PHPMA), polyacrylamide, poly(2-hydroxyethyl methacrylate), poly(2-methacryloxyethyl sulfonic acid), poly(methacryloxyethyl trimethyl ammonium chloride), poly(vinyl pyridine), and
poly[poly(ethylene glycol) methacrylate]. In some embodiments, a biocompatible polymer (B) is selected from the group consisting of:
wherein each n is independently an integer from 0 to 30.
A targeting group (C) can be selected from the group consisting of: polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. In some embodiments, the targeting group (C) further comprises a linking group. For example, the targeting group can be selected from:
In some embodiments, the random copolymer can further comprise from about 10 to about 100% by weight D, wherein D is a fluorescent oxygen sensor. For example, the sum of A, B, C, and D are 100% by weight of the copolymer. In some embodiments, a fluorescent oxygen sensor (D) can include a compound having the formula:
or a salt form thereof, wherein: M is Pt or Pd; Rl5 R2, R3, R4, R5, and R6 are
independently selected from the group consisting of: H, F, CI, Br, I, CH3, OCH3, and OC2H5; R7, R8, R9, and R10 are independently selected from the group consisting of: (CH2)nOH, 0(CH2)nOH, NH(CH2)nOH, (CH2)„OW, 0(CH2)nOW, NH(CH2)„O , (OCH2CH2)nOH, NH(CH2CH20)nH, (OCH2CH2)nOW, NH(CH2CH20)nW; W is selected from the group consisting of:
n is an integer from 0 to 10. For example, D can be:
This disclosure also provides a nanoparticle comprising polymerized monomers of one or more compounds of formula (1) and (2). In some embodiments, the
nanoparticles can further comprise polymerized monomers of a targeting group (e.g., folic acid and cRGD), biocompatible polymer, and/or fluorescent oxygen sensor or pH sensor as described herein. For example, the monomers can be polymerized in a random copolymer. In some embodiments, the diameter of the nanoparticle is about 1 nm to about 300 nm.
The polymerized monomers of formula (1) and (2) can also be used in a polymer thin film. In some embodiments, the thin film is formed on a substrate. For example, glass (e.g., organic or inorganic glass), transparent polymer, and transparent copolymer polymeric mixture. In some embodiments, the substrate is selected from the group consisting of plasticized or non-plasticized poly( vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof. In some embodiments, the substrate is quartz glass. In other embodiments, the substrate is an optic fiber bundle. The thickness of the polymer thin film can be from about 0.1 to about 100 μιη.
Also provided herein is a sensing film comprising a substrate, as described above, covalently bound to a compound of formula (1) and/or (2). In some embodiments, the compound is covalently bound to the substrate through a linker. The sensing film can further comprise, for example, a fluorescent oxygen sensor, a fluorescent pH sensor, or mixtures thereof.
Intracellular sensors as described herein can also include a targeted compound having the formula:
m is 0 or 1 ; n is 0 or 1 ; L is a linker; and Y is a targeting group.
A targeted compound includes, for example, a compound having the formula:
A targeting group can include, for example, polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. In some embodiments, the targeting group is selected from the group consisting of: folic acid, cyclo(arginine-glycine-aspartic acid) (cRGD), TAT peptides, and galactose. Non-limiting examples of a targeted compound include:
This disclosure also provides a method of measuring potassium ion concentration in a sample. In some embodiments, the method can include contacting the sample with a compound of formula (1), formula (2), or a targeted compound and measuring the fluorescence emitted by the compound. In some embodiments, the sample is a fluid sample. For example, a fluid sample comprising one or more cells. The potassium ion concentration can be measured in the extracellular fluid of the sample or in the intracellular fluid of the cells.
For example, a method of measuring potassium ion concentration in a cell is provided, the method comprising contacting the cell with a compound as described herein and measuring the fluorescence emitted by the compound. In some embodiments, the
fluorescence is measured using spectrofluorimetry. Any suitable cell can be used, for example, a cancer cell. In some embodiments, the compound is contacted with the cell using microinjection. The compounds described herein can be used as discrete compounds or as a polymerized monomer in a polymer thin film or a nanoparticle. For example, in some embodiments the compound is covalently attached to a surface.
In addition, a method of imaging a cancer cell in a patient is provided, the method comprising administering to the patient an effective amount of a compound as described herein and imaging the patient.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF DRAWINGS
FIG. 1 is a schematic illustration of the preparation of a sensing film: (a) oxygen plasma treatment is used to generate active hydroxyl groups; (b) vapor deposition of thin trimethylsilylpropyl acrylate (TMPSA) layer; (c) 25 μπι tape used to control membrane thickness; (d) sensor solution dispensed onto modified quartz surface; (e) solution covered with a cover glass and polymerized at 80°C for 1.5 h; (f) cover glass and tape removed; film rinsed using methanol and double-distilled water; and (g) sensing membrane responding to potassium ions.
FIG. 2 illustrates the potassium ion response for a sensor of Example 1 for intracellular potassium ion sensing.
FIG. 3 illustrates the potassium ion response of a sensor of Example 2 for intracellular potassium ion sensing.
FIG. 4 shows the fluorescent imaging of cells using a sensor of Example 1.
FIG. 5 shows the fluorescent imaging of cells using a sensor of Example 2.
FIG. 6 shows the extracellular potassium sensing of a sensor film having polymerized monomers of a sensor of Example 1.
FIG. 7 shows the detection of potassium and oxygen in a dual sensor film.
FIG. 8A shows the fluorescence change of 2(a) in HEPES buffer (pH 7.2) containing different KC1 concentrations, excited at 561 nm. 8B illustrates the changes of fluorescence intensities at 650 nm at different K+ concentrations. F is the fluorescence intensity at various conditions. FQ is the emission intensity before the titration (with 0 mM K+). 8C is a Benesi-Hildebrand plot of 2(a). 8D shows the fluorescence intensity change of 2(a) in the presence of various biological cations at their physiological concentrations [K+ (150 mM), Na+ (15 mM), Ca2+ (2.0 mM), Mg2+ (2.0 mM), Zn2+ (2.0 mM), Fe3+ (50 μΜ), Mn2+ (50 μΜ), and Cu2+ (50 μΜ)] and different pH values [pH (5.0) and pH (8.0)].
FIG. 9A illustrates the responses of 2(a) to sodium ion, potassium ion, and potassium ion at 140 mM sodium ion condition. 9B shows 2(a) 's responses to sodium ion, calcium ion, magnesium ion, and potassium ion.
FIG. 10 displays confocal fluorescence images of 2(a) (4 μΜ) in U87MG cells co- stained with Hoechst 33342 (10 μΜ). 10(a) is a red emission from 2(a) excited at 561 nm; 10(b) is a blue emission from Hoechst 33342 excited at 405 nm; 10(c) shows an overlay of (a) and (b).
FIG. 11 shows confocal fluorescence images of U87MG cells. 11 A depicts the green fluorescence image of cells stained with MitoTracker® Green. 11B depicts the red fluorescence image of cells stained by 2(a). 11C is the overlay of 11A and 11B. 11D is the bright field image of cells.
FIG. 12 shows confocal fluorescence images of U87MG cells. 12A depicts the green fluorescence image of cells stained by SM3. 12B depicts the red fluorescence image of cells stained by 2(a). 12C is the overlay of 12A and 12B. 12D is the bright field image of cells. 12E is the chemical structure of SM3.
FIG. 13 illustrates the time-dependent intracellular K+ in U87MG cells after treatment with a mixture of nigericin, bumetanide, and ouabain for 0 min (13a and 13b), 60 minutes (13c and 13d), and 120 minutes (13e and 13f). Top: fluorescence images; Bottom: bright field images. Concentrations of 2(a), nigericin, bumethanide, and ouabain for this study were 4 μΜ, 5 μΜ, 10 μΜ, and 10 μΜ, respectively.
FIG. 14 provides fluorescence images of 2(a) at high concentrated KC1 (20 mM) and isoproterenol (5 μM)-containing medium. 14a and 14c are fluorescence images. 14b
and 14d are the fluorescence images superimposed with bright field images. 14a and 14b are for time of 0. 14c and 14d are for time of 40 minutes. Average fluorescence intensity increased 33% by the isoproterenol stimulation analyzed using ImageJ.
FIG. 15 shows the time-dependent fluorescence of U87MG cells stimulated by nigericin observed under confocal fluorescence microscope. 15a is time of 0 before the addition of nigericin; 15b, 15c, 15d, 15e, 15f, and 15g are time of 1, 3, 5, 10, 15 and 25 minutes, respectively, after the addition of nigericin (20 μΜ, final concentration) into the 20 mM KCl-containing medium; 15h gives the average fluorescence intensity ratios measured by ImageJ. 10 is the average fluorescence intensity from FIG. 15 a; I is the average fluorescence intensity at different times.
FIG. 16 is a schematic illustration of the preparation of sensing membranes, a) oxygen plasma treatment to generate active hydroxyl groups; b) vapor deposition of thin TMSPA layer; c) 25-mm tape used to control membrane thickness; d) sensor solution dispensed onto modified quartz surface; e) solution covered with a cover glass and polymerized at 80°C for 1.5 hours; f) cover glass and tape removed; film rinsed using methanol and double-distilled water; and g) sensing membrane on quartz substrate immersed into liquid in cuvette for fluorescence measurements.
FIG. 17A is a UV-Vis spectra of 1(a) at 0 mM and 200 mM potassium chloride (KC1) conditions. 17B shows the fluorescence spectral change of 1(a) in 10 mM HEPES buffer containing different C1 concentrations using an excitation wavelength at 450 nm. 17C provides the change of fluorescence intensity at 525 nm at different potassium ion concentrations. F is the fluorescence intensity at various conditions. F0 is the emission intensity before the titration (with 0 mM K+). 17D is the Benesi-Hildebrand plot of 1(a). 17E shows the fluorescence intensity change of 1(a) in the presence of various biological cations at their physiological concentrations: Na+ (15 mM), Ca2+ (0.5 mM), Mg2+ (2.5 mM), Fe3+ (18 mM), Zn2+ (45 mM), Mn2+ (0.9 mM), and Cu2+ (16 mM).
FIG. 18A is an emission intensity change of the l(a)-conjugated PHEMA-co-PAM (F4) with KC1 in buffer. 18B illustrates the change of fluorescence intensity at 525 nm at different KC1 and NaCl concentrations. F is the fluorescence intensity at various conditions. F0 is the emission intensity before titration (with 0 mM K+). 18C is a Benesi- Hildebrand plot of F4. 18D shows the influence of pH values on the fluorescence
intensities at 525 nm of F4 film before and after the complexation with variable potassium ions.
FIG. 19A shows the fluorescence intensity changes of Fl, F2, F3, and F4 titrated using KC1 in the concentration range of 0 to 10 mM. 19B illustrates the fluorescence intensity changes of F4, F5, F6, F7, and F8 titrated using KC1 in the concentration range of O to 10 mM.
FIG. 20 illustrates the confocal fluorescence images of CP -A (A-D) and U87MG (E-H) cells. 20A and 20E depict the blue channel, showing nuclei stained with Hoechst 33342. 20B and 20F depict the green channel, showing the loading of 1(a) into the cells. 20C and 20G depict the red channel, showing lysosomes loaded with LysoTracker Red®. 20D is the overlay of 20 A, 20B and 20C. 20H is the overlay of 20E, 20F and 20G.
FIG 21 shows the fluorescence change of cells loaded with 1(a) stimulated with ATP, amphotericin (amphoB), nigericin (Nig), and the mixture of nigericin, bumetanide, and ouabain (N+B+O). 21 A represents the U87MG cell line. 21B represents the CP-A cell line. Concentrations of the stimuli materials were: ATP (100 μΜ), nigericin (5 μΜ), amphotericin B (3.25 μΜ), bumetanide (10 μΜ), and ouabain (10 μΜ). 444 nm was used as the excitation wavelength and emission was measured at 538 nm using a microplate reader.
FIG. 22 show the effect of lysozyme on K+-release from E. coli (22A) and B. subtilis (22B) visualized by F4 film.
DETAILED DESCRIPTION
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications cited herein are incorporated by reference in their entirety. In the event that
there is a plurality of definitions for terms cited herein, those in this section prevail unless otherwise stated.
For the terms "for example" and "such as," and grammatical equivalences thereof, the phrase "and without limitation" is understood to follow unless explicitly stated otherwise. As used herein, the term "about" is meant to account for variations due to experimental error. All measurements reported herein are understood to be modified by the term "about", whether or not the term is explicitly used, unless explicitly stated otherwise. As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
The term "salt" includes any ionic form of a compound and one or more counter- ionic species (cations and/or anions). Salts also include zwitterionic compounds (i.e., a molecule containing one more cationic and anionic species, e.g., zwitterionic amino acids). Counter ions present in a salt can include any cationic, anionic, or zwitterionic species. Exemplary anions include, but are not limited to: chloride, bromide, iodide, nitrate, sulfate, bisulfate, sulfite, bisulfite, phosphate, acid phosphate, perchl orate, chlorate, chlorite, hypochlorite, periodate, iodate, iodite, hypoiodite, carbonate, bicarbonate, isonicotinate, acetate, trichloroacetate, trifluoroacetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate,
methanesulfonate, trifluormethansulfonate, ethanesulfonate, benzensulfonate, p- toluenesulfonate, p-trifluoromethylbenzenesulfonate, hydroxide, aluminates and borates. Exemplary cations include, but are not limited to: monovalent alkali metal cations, such as lithium, sodium, potassium, and cesium, and divalent alkaline earth metals, such as beryllium, magnesium, calcium, strontium, and barium. Also included are transition metal cations, such as gold, silver, copper and zinc, as well as non-metal cations, such as ammonium salts.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from nontoxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 a d Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. Conventional methods for preparing salt forms are described, for example, in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley- VCH, 2002.
The compounds described herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
The reactions for preparing the compounds can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid
chromatography-mass spectroscopy (LCMS) or thin layer chromatography (TLC).
Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) ("Preparative LC-MS Purification: Improved Compound Specific Method Optimization " .F. Blom, et al., J. Combi. Chem. 6(6) (2004), which is incorporated herein by reference in its entirety) and normal phase silica chromatography.
Sensing Compounds
Provided herein are potassium sensing molecules of formula (1):
(1)
or a salt form thereof, wherein m is 0 or 1 ; n is an integer from 0 to 3; and X is selected from:
or a salt form thereof.
A compound of formula (1) can be prepared, for example, as shown in Scheme 1 and described in Examples 1 and 18. In particular, a compound of formula (1) may be prepared upon reaction of an amino compound (I) and a halo compound (II) in the presence of any reagent which would achieve formation of the compound of the N-aryl amine. For example, an amine of compound (I) can be reacted with a halo compound (II) in the presence of a base. Suitable bases include non-nucleophilic bases such as N,N- diisopropylethylamine (DIPEA), carbonate salts (e.g., K2C03 and Cs2C03), triethylamine (TEA), pyridine, tributylamine, and l,8-diazabicycloundec-7-ene (DBU).
Scheme 1
I
Also provided herein are potassium sensing compounds of formula (2):
n is an integer from 0 to 3 (e.g., 0, 1, 2, and 3); X is selected from: H, OH,
Formula (2) can include, for example,
31
32
33
or a salt form thereof.
A compound of formula (2) can be prepared, for example, as shown in Scheme 2 and described in Examples 2 and 10. In particular, a compound of formula (2) may be prepared upon the condensation of an aldehyde compound (III) and a compound (IV) in the presence of any reagent which would achieve formation of targeted probes as potassium ion sensors. For example, an aldehyde of compound (III) can be reacted with an activated compound (IV) in the presence of a catalyst. Suitable catalysts include, but are not limited to, bases such as ammonium acetate, pyridine, diisopropylethyl amine, triethyl amine, lithium ethoxide, and piperidine.
Scheme 2
In some embodiments, the compounds described herein may be modified to contain targeting groups. For example, a compound of formula (3):
or a salt form thereof, wherein m is 0 or 1 ; L is a linker; and Y is a targeting group.
Suitable targeting groups include specific and nonspecific targeting groups. For example, nonspecific targeting groups can be used to enhance nonspecific uptake the compounds through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake. Non-limiting examples of suitable nonspecific targeting groups include: glucose, sugar, dimethyl amine, diethyl amine, tetraalkyl ammonium salt, poly(dimethylaminoethyl methacrylate) (PDMEM) and poly(aminoethyl methacrylamide) (PAMEM).
Specific targeting groups can also be used to enhance specific cellular uptake of the potassium sensors. Non-limiting examples of suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. For
example, folic acid can facilitate specific uptake of the compound by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells. In some embodiments, use of a polypeptide can facilitate specific uptake by targeted cells. For example, cyclic(arginine- glycine-aspartic acid) (cRGD) can target uptake by avP3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells.
A linker can be any suitable organic group which serves to space the sensor from the targeting group so as to maximize uptake and/or sensing. In some embodiments, L and Y are covalently bound to one another. For example, a linker can include one or more of a C1-20 alkyl, C1-2o alkoxy, amino, and thiol moiety. In some embodiments, the linker can include a pyrrole-2,5-dione. The linker may also include a polyethylene glycol (PEG) linker. Examples of such linkers are well known to those skilled in the art. In some cases the linker and targeting group are noncovalently bound to one another.
Examples of noncovalent means for conjugation of a linker and a targeting group include, e.g., ionic bonding, hydrophobic interactions, ligand-nucleotide binding, chelating agent/metal ion pairs or specific binding pairs such as avidin/biotin, streptavidin/biotin, anti-fluorescein/fluorescein antibodies, anti-2,4-dinitrophenol (DNP)/DNP antibodies, anti-peroxidase/peroxidase, anti-digoxigenin/digoxigenin or, more generally,
receptor/ligand.
Non-limiting examples of a compound of formula (3) include:
A compound of formula (3) can be prepared, for example, as shown in Schemes 3 and 4. In particular, a compound of formula (3) may be prepared upon the coupling of amine derivative of a compound of formula (1) or (2) and a targeting group in the presence of any reagent which would achieve formation of a peptide bond. For example, as shown in Scheme 3, an amine derivative of a compound of formula (1) can be directly linked to folic acid in the presence of a coupling agent. Suitable coupling agents include, but are not limited to, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), Ν,Ν'-dicyclohexylcarbodiimide (DCC), ArB(OH)2 reagents, Sn[N-(TMS)2]2, Ν,Ν'-carbonyldiimidazole, POCl3, T1CI4, molecular sieves, Lawesson's reagent, and
(Me02)POCl. See, for example, Klausner, Y.S. and Bodansky, M. Synthesis, 1972, 453, which is incorporate herein in its entirety. Alternatively, as shown in Scheme 4, an amine derivative of a compound of formula (1) can be reacted with a linker (e.g., 3-(2,5-dioxo- 2,5-dihydro-lH-pyrrol-l-yl)propanoic acid) in the presence of a coupling agent as described above. The resulting derivative of the compound of formula (1) can then be reacted with a typical targeting group possessing a thio (-SH)-containing cRGD moiety, e.g., cyclo(Arg-Gly-Asp-D-Phe-Cys) or cRGDfc in DMSO or buffers (HEPES, PBS, or Tris HC1) through Michael addition reaction.
Scheme 3
Scheme 4
Polymers
Further provided herein are polymers composed of one or more polymerized monomers of a compound of formula (1) as described above. In some embodiments, a polymer comprises one or more polymerized monomers of a compound of formula (2A):
n is an integer from 0 to 3 (e.g., 0, 1, 2, and 3); and X is selected from:
A polymer may be prepared by reacting two or more monomer compounds of formula (1) and/or formula (2 A) in the presence of any reagent which would achieve formation of a polymer. In some embodiments, two or more monomer compounds are coupled through thermal polymerization in the presence of a thermal initiator to form a polymer. Suitable thermal initiators include, for example, aliphatic azo compounds such as azobisisobutyronitrile (AIBN), 4,4-azobis(4-cyanovaleric acid), and 1,1'- azobis(cyclohexanecarbonitrile) (ABCN), and organic peroxides such as benzoyl peroxide (BPO), di-t-butylperoxide (tBuOOtBu), methyl ethyl ketone peroxide, lauroyl peroxide, and acetone peroxide, and potassium persulfate. Alternatively, two or more monomer compounds can be coupled through photopolymerization in the presence of a photo-initiator. Suitable photo initiators include, for example, benzophenone, 2,2- dimethoxy-2-phenylacetophenone (DMPA), 2,2-dimethoxyphenylacetophenone (Irgacure 851), and bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide (Irgacure 819).
In some embodiments, the polymer may be formed into a polymer thin film. The polymer thin film can have a thickness ranging from about 0.1 to about 100 μιη (e.g., from about 0.5 to about 100 μηι; from about 1 to about 100 μπι; from about 10 to about 100 μιη; from about 25 to about 100 μπι; from about 40 to about 100 μιη; from about 55 to about 100 μπι; from about 65 to about 100 μπι; from about 80 to about 100 μηι; from about 0.1 to about 90 μιη; from about 0.1 to about 75 μηι; from about 0.1 to about 60 μηι; from about 0.1 to about 40 μιη; from about 0.1 to about 15 μηι; from about 0.1 to about 5 μιη; from about 0.1 to about 1 μηι; from about 5 to about 75 μηι; from about 10 to about 80 μηι; from about 15 to about 65 μιη; and from about 25 to about 50 μιη).
In some cases, the polymer thin film may be formed on a substrate, for example, glass, a transparent polymer, or a transparent copolymer polymeric mixture. Suitable substrates include, for example, plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof. In some embodiments, the substrate is an organic or inorganic glass, for example, quartz glass. Alternatively, the substrate can be an optic fiber bundle.
In some embodiments, a random copolymer is provided. A random copolymer can comprise one or more compounds (A) of formula (1) or (2A), one or more biocompatible polymers (B), and one or more targeting groups (C).
Compound (A) can include one or more compounds of formula (1) or (2 A) as described above. In some embodiments, a random copolymer can include from about 0.01 to about 10% by weight of a compound (A) (e.g., from about 0.1 to about 10%; from about 0.5 to about 10%; from about 1 to about 10%; from about 2 to about 10%; from about 4 to about 10%; from about 6 to about 10%; from about 8 to about 10%; from about 0.01 to about 8%; from about 0. 01 to about 7%; from about 0.01 to about 5%; from about 0.01 to about 3%; from about 0.01 to about 1.5%; from about 0.01 to about 0.8%; from about 0.01 to about 0.4%; from about 0.01% to about 0.1%; from about 0.4% to about 4%; from about 0.75% to about 2.5%; from about 1% to about 6%; from about 3% to about 8%; and from about 2.5% to about 7.5%).
Compound (B) can be any suitable biocompatible polymer. Suitable
biocompatible polymers include, for example, dextran, chitosan, glycol chitosan, poly-L- lysine, poly-aspartic acid, PEG and derivatives thereof, poly(amino acid)s, poly(N- isopropyl acrylamide) (PNIPAAm), poly(dimethylamnioethyl methacrylate) (PDMEM), poly(aminoethyl methacrylamide) (PAMEM), poly[( -2-hydroxypropyl)
methacrylamide] (PHPMA), polyacrylamide, poly(2-hydroxyethyl methacrylate), poly(2- methacryloxyethyl sulfonic acid), poly(methacryloxyethyl trimethyl ammonium chloride), poly(vinyl pyridine), and poly[poly(ethylene glycol) methacrylate]. In some embodiments, a compound (B) is selected from:
O o
0(CH2CH20)nH OCH2CH2N(CH3)2
wherein each n is independently an integer from 0 to 30. In some embodiments one or more compound (B) monomers are incorporated into the random copolymer.
A random copolymer can include from about 10 to about 90% by weight of a compound (B) (e.g., from about 10 to about 85%; from about 10 to about 75%; from about 10 to about 66%; from about 10 to about 52%; from about 10 to about 46%; from about 10 to about 37%; from about 10 to about 30%; from about 10 to about 26%; from about 10 to about 13%; from about 15% to about 90%; from about 26% to about 90%; from about 32% to about 90%; from about 40% to about 90%; from about 55% to about 90%; from about 64% to about 90%; from about 77% to about 90%; from about 15 to about 85%; from about 20 to about 70%; from about 25 to about 75%; from about 35 to about 66%; and from about 40 to about 60%).
Suitable targeting groups (C) include specific and nonspecific targeting groups. For example, nonspecific targeting groups can be used to enhance nonspecific uptake the compounds through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake. Non-limiting examples of suitable nonspecific targeting groups include: glucose, dimethyl amine, diethyl amine, tetraalkyl ammonium salts, poly(dimethylaminoethyl methacrylate) (PDMEM) and poly(aminoethyl methacrylamide) (PAMEM).
Specific targeting groups can also be used to enhance specific cellular uptake of the polymers. Non-limiting examples of suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. For example, folic acid can facilitate specific uptake of the compound by folate receptor rich/over
expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells. In some embodiments, use of a polypeptide can facilitate specific uptake by targeted cells. For example, cyclic(arginine- glycine-aspartic acid) (cRGD) can target uptake by vp3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells.
A targeting group compound (C) can include:
A random copolymer can include from about 10 to about 90% by weight of a compound (C) (e.g., from about 10 to about 85%; from about 10 to about 75%; from about 10 to about 66%; from about 10 to about 52%; from about 10 to about 46%; from about 10 to about 37%; from about 10 to about 30%; from about 10 to about 26%; from about 10 to about 13%; from about 15% to about 90%; from about 26% to about 90%; from about 32% to about 90%; from about 40% to about 90%; from about 55% to about 90%; from about 64% to about 90%; from about 77% to about 90%; from about 15 to about 85%; from about 20 to about 70%; from about 25 to about 75%; from about 35 to about 66%; and from about 40 to about 60%). In some embodiments one or more compound (C) monomers are incorporated into the random copolymer.
In some embodiments, the sum of A, B, and C is 100% of the weight of the random copolymer. Alternatively, in some cases, the random copolymer comprises a fluorescent oxygen sensor, a fluorescent pH sensor, or a combination thereof. For example, a random copolymer can comprise from about 0.01 to about 10% by weight of a compound (A); from about 10 to about 90% by weight of a compound (B); from about 10 to about 90% by weight of a compound (C); and from about 0.01 to about 10% by weight of a compound (D), wherein the compounds of (A), (B), and (C) are as described above, and a compound (D) is a fluorescent oxygen sensor, a fluorescent pH sensor, or a combination thereof.
Any suitable fluorescent oxygen sensor, or derivative thereof, capable of being polymerized can be used in the random polymers described herein. For example, an oxygen sensor of formula (4):
or a salt form thereof, wherein M is Pt or Pd; Rl5 R2, R3, R4, R5, and 3 are independently selected from the group consisting of: H, F, CI, Br, I, C¾, OCH3, OC2H5; R7, R8, R9, and R10 are independently selected from the group consisting of: (CH2)nOH, 0(CH2)nOH, NH(CH2)nOH, (CH2)nOW, 0(CH2)nOW, NH(CH2)nOW, (OC¾CH2)nOH,
NH(CH2CH20)nH, (OCH2CH2)nOW, H2CH20)nW; W is selected from:
n is an integer from 0 to 10.
A compound of formula (4) can include, for example:
Any suitable fluorescent sensor, or derivative thereof, capable of being polymerized (e.g., having a vinyl moiety) can be used in a random copolymer as described herein. For example, the pH sensor molecules described in U.S. Patent No. 7,390,462, which is herein incorporated by reference in its entirety.
A random copolymer can include from about 0.01 to about 10% by weight of a compound (D) (e.g., from about 0.1 to about 10%>; from about 0.5 to about 10%; from about 1 to about 10%>; from about 2 to about 10%; from about 4 to about 10%; from about 6 to about 10%; from about 8 to about 10%>; from about 0.01 to about 8%>; from about 0. 01 to about 7%; from about 0.01 to about 5%»; from about 0.01 to about 3%; from about 0.01 to about 1.5%; from about 0.01 to about 0.8%>; from about 0.01 to about 0.4%; from about 0.01% to about 0.1%; from about 0.4% to about 4%; from about 0.75% to about 2.5%; from about 1% to about 6%; from about 3% to about 8%; and from about 2.5% to about 7.5%).
In some embodiments, the sum of A, B, C, and D is 100% of the weight of the random copolymer.
A random copolymer can be prepared through reaction of the monomers described above in the presence of any reagent which would achieve formation of a polymer. In some embodiments, two or more monomer compounds are coupled through thermal polymerization in the presence of a thermal initiator to form a polymer. Suitable thermal initiators include, for example, aliphatic azo compounds such as
azobisisobutyronitrile (AIBN), 4,4-azobis(4-cyano valeric acid), and 1,1'- azobis(cyclohexanecarbonitrile) (ABCN), and organic peroxides such as benzoyl peroxide (BPO), di-t-butylperoxide (tBuOOtBu), methyl ethyl ketone peroxide, and
acetone peroxide. Alternatively, two or more monomer compounds can be coupled through photopolymerization in the presence of a photo-initiator. Suitable photo initiators include, for example, benzophenone, 2,2-dimethoxy-2-phenylacetophenone (DMPA), 2,2-dimethoxyphenylacetophenone (Irgacure 851), and bis(2,4,6- trimethylbenzoyl)-phenylphosphineoxide (Irgacure 819).
For example, all of the desired monomers (e.g., monomers of formula (1) and/or formula (2A), monomers of compound (B), monomers of compound (C), and/or monomers of compound (D)) can be polymerized in the presence of an initiator as described above in suitable solvents, such as DMF, DMSO, ethanol, THF, and toluene. In some embodiments, the polymerization is performed under inert atmospheric conditions (e.g., N2 or Ar). The resulting polymers can be collected, for example, by precipitating the polymers and further purification (e.g., by fraction and dialysis) can be performed as needed.
In some embodiments, the random copolymer may be formed into a polymer thin film. The polymer thin film can have a thickness ranging from about 0.1 to about 100 μιη (e.g., from about 0.5 to about 100 μηι; from about 1 to about 100 μιη; from about 10 to about 100 μη ; from about 25 to about 100 μκα; from about 40 to about 100 μηι; from about 55 to about 100 μηι; from about 65 to about 100 μηι; from about 80 to about 100 μιη; from about 0.1 to about 90 μηι; from about 0.1 to about 75 μιη; from about 0.1 to about 60 μηι; from about 0.1 to about 40 μπι; from about 0.1 to about 15 μπι; from about 0.1 to about 5 μιη; from about 0.1 to about 1 μη ; from about 5 to about 75 μιη; from about 10 to about 80 μηι; from about 15 to about 65 μηι; and from about 25 to about 50 μιη).
In some cases, the random copolymer thin film may be formed on a substrate, for example, glass, a transparent polymer, or a transparent copolymer polymeric mixture. Suitable substrates include, for example, plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide,
polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof. In some embodiments, the substrate is an organic or inorganic glass, for example, quartz glass. Alternatively, the substrate can be an optic fiber bundle.
A polymer or random copolymer having one or more terminal amine moieties can be postfunctionalized with a targeting group. Suitable targeting groups (C) include specific and nonspecific targeting groups. For example, nonspecific targeting groups can be used to enhance nonspecific uptake the polymer through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake. Non- limiting examples of suitable nonspecific targeting groups include: glucose, dimethyl amine, diethyl amine, poly(dimethylaminoethyl methacrylate) (PDMEM) and
poly(aminoethyl methacrylamide) (PAMEM).
Specific targeting groups can also be used to enhance specific cellular uptake of the polymers. Non-limiting examples of suitable specific targeting groups include polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. For example, folic acid can facilitate specific uptake of the compound by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human
nasopharyngeal epidermal carcinoma KB cells. In some embodiments, use of a polypeptide can facilitate specific uptake by targeted cells. For example, cyclic(arginine- glycine-aspartic acid) (cRGD) can target uptake by avp3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells. Nanoparticles
Provided herein are nanoparticles comprising one or more polymerized monomer compounds of formula (1) or (2 A) as described above. In some embodiments, a nanoparticle can be prepared as a random copolymer as described above.
A nanoparticle, as described herein, can be prepared using methods known to those of skill in the art. For example, a nanoparticle can be prepared through emulsion polymerization. In some embodiments, a nanoparticle can be prepared by combining all desired monomers (e.g., monomers of formula (1) and/or formula (2A), monomers of compound (B), monomers of compound (C), and/or monomers of compound (D)) in water with a suitable surfactant and a suitable initiator. Suitable surfactants can include, for example, fatty acids, sodium dodecyl sulfate (SDS), and alpha olefin sulfonate. In some embodiments, a surfactant can be chosen from Tween 20 and SDS. Suitable
initiators include, for example, aliphatic azo compounds such as 4,4-azobis(4- cyanovaleric acid), azobisisobutyronitrile (AIBN) and Ι,Γ- azobis(cyclohexanecarbonitrile) (ABCN), and peroxides such as benzoyl peroxide (BPO), di-t-butylperoxide (tBuOOtBu), methyl ethyl ketone peroxide, lauroyl peroxide, acetone peroxide and hydroperoxide. In some embodiments, the nanoparticle is prepared under inert atmospheric conditions (e.g., N or Ar). Nanoparticles can be purified following polymerization, for example by dialysis.
Nanoparticles may have a diameter from about 1 nm to about 300 nm (e.g., from about 1 nm to about 250 nm, from about 1 nm to about 200 nm, from about 1 nm to about 150 nm, from about 1 nm to about 125 nm, from about 1 nm to about 100 nm, from about 1 nm to about 75 nm, from about 1 nm to about 60 nm, from about 1 nm to about 45 nm, from about 1 nm to about 25 nm, from about 1 nm to about 10 nm, from about 5 nm to about 300 nm, from about 25 nm to about 300 nm, from about 50 nm to about 300 nm, from about 75 nm to about 300 nm, from about 100 nm to about 300 nm, from about 125 nm to about 300 nm, from about 140 nm to about 400 nm, from about 200 nm to about 300 nm, from about 25 to about 150 nm, from about 50 to about 125 nm, from about 75 to about 125 nm, from about 80 to about 120 nm, and from about 90 to about 110 nm). In some embodiments, the nanoparticles have a diameter less than about 100 nm. The sizes of the nanoparticles can be characterized using, for example, dynamic light scattering (DLS), atomic force microscopy (AFM), scanning electron microscopy (SEM), or transmission electron microscopy (TEM).
A nanoparticle having one or more terminal amine moieties can be
postfunctionalized with a targeting group. Suitable targeting groups (C) include specific and nonspecific targeting groups. For example, nonspecific targeting groups can be used to enhance nonspecific uptake the compounds through the incorporation of groups capable of interacting with the cellular membrane to enhance cellular uptake. Non- limiting examples of suitable nonspecific targeting groups include:
poly(dimethylaminoethyl methacrylate) (PDMEM) and poly(aminoethyl
methacrylamide) (PAMEM).
Specific targeting groups can also be used to enhance specific cellular uptake of the nanoparticles. Non-limiting examples of suitable specific targeting groups include
polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. For example, folic acid can facilitate specific uptake of the nanoparticles by folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human
nasopharyngeal epidermal carcinoma KB cells. In some embodiments, use of a polypeptide can facilitate specific uptake by targeted cells. For example, cyclic(arginine- glycine-aspartic acid) (cRGD) can target uptake by avp3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells. Sensing film for extracellular detection of ions
Further provided herein are sensing films comprising a substrate covalently bound to a compound of formula (1) or (2A). In some embodiments, the substrate is covalently bound to the compound through a linker. A linker can be any suitable organic group which serves to space the substrate from the compound so as to enable the sensing film to be chemically immobilized on the substrates, maximize sensing sensitivity or signal intensity. For example, a linker can include one or more of a C1-20 alkyl, C^o alkoxy, amino, silane, maleimide, and thiol moiety. The linker may also include a polyethylene glycol (PEG) linker. In some embodiments, the linker can include a vinyl, acrylate, or methacrylate moiety to facilitate polymerization of the compound of formula (1) or (2 A) to the linker. Examples of such linkers are well known to those skilled in the art.
A substrate can be any substrate suitable for the preparation of sensing membranes. For example, a substrate can include glass, a transparent polymer, or a transparent copolymer polymeric mixture. Suitable substrates also include, for example, plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials,
polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof. In some embodiments, the substrate is an organic or inorganic glass, for example, quartz glass. Alternatively, the substrate can be an optic fiber bundle.
In some embodiments, a crosslinker comprises at least two of the following: a vinyl, acrylate, methacrylate, acrylamide, and methacrylamide functional group. For
example, the crosslinkers can include poly(ethylene glycol) dimethacrylate, ethoxylated trimethylolpropane triacrylate (SR454), and bio(ethylamine)acryamide.
In some embodiments, the sensors were copolymerized into suitable matrices. For example, an ion permeable matrix such as poly(2-hydroxyethyl methacrylate), poly(acrylamide), poly[(ethylene glycol) methacrylate] can be used.
A sensing film as described herein can be prepared, for example, as shown in FIGs. 1 and 16. In particular, the sensing film can be prepared by reacting a compound of formula (1) or (2A) with an initiator in the presence of matrix monomers such as the 2- hydroxyethyl methacrylate, acrylamide and a crosslinker in a solvent (e.g., DMF), or a functionalized substrate (e.g., an acrylate-moiety functionalized quartz glass).
Polymerization can be carried out under inert atmosphere and at elevated temperature. The sensing film prepared can then be purified as needed to remove any non-polymerized monomers or residual solvent. Fluorescence Assays
Fluorescence of a sensor (e.g., compound, polymer, nanoparticle, and sensing film) as described herein may be detected by any suitable fluorescence detection device. Such devices are typically comprised of a light source for excitation of the fluorophore and a sensor for detecting emitted light. In addition, fluorescence detection devices typically contain a means for controlling the wavelength of the excitation light and a means for controlling the wavelength of light detected by the sensor (e.g., filters, diffraction gratings, and dichroic mirrors). Examples of suitable devices include fluorimeters, spectrofluorimeters and fluorescence microscopes. Many such devices are commercially available from companies such as Hitachi, Nikon, Molecular Dynamics or Zeiss. In some embodiments, the device is coupled to a signal amplifier and a computer for data processing.
In general, assays using a sensor as provided herein involve contacting a sample with such a sensor and measuring fluorescence. For example, methods are provided for measuring the concentration of potassium ions in a sample. In some cases, the concentration of oxygen and hydronium ions (pH) may also be determined. The presence of an analyte (e.g., potassium ion, oxygen, or hydronium ion) that interacts with the
sensor may alter fluorescence of the sensor in many different ways. Essentially any change in fluorescence caused by the analyte, typically the potassium ion, may be used to determine the presence of the ion and, optionally, the concentration of the ion in the sample.
The change may take one or more of several forms, including a change in excitation or emission spectra, or a change in the intensity of the fluorescence and/or quantum yield. These changes may be either in the positive or negative direction and may be of a range of magnitudes, which preferably will be detectable as described below.
The excitation spectrum is the wavelengths of light capable of causing the sensor to fluoresce. To determine the excitation spectrum for a sensor in a sample, different wavelengths of light are tested sequentially for their abilities to excite the sample. For each excitation wavelength tested, emitted light is measured. Emitted light may be measured across an interval of wavelengths (for example, from 450 to 700 nm) or emitted light may be measured as a total of all light with wavelengths above a certain threshold (for example, wavelengths greater than 500 nm). A profile is produced of the emitted light produced in response to each tested excitation wavelength, and the point of maximum emitted light can be referred to as the maximum excitation wavelength. A change in this maximum excitation wavelength, or a change in the shape of the profile caused by ion in a sample may be used as the basis for determining the presence, and optionally, the concentration of ion in the sample. Alternatively, the emission spectrum may be determined by examining the spectra of emitted light in response to excitation with a particular wavelength (or interval of wavelengths). A profile of emissions at different wavelengths is created and the wavelength at which emission is maximal is called the maximum emission wavelength. Changes in the maximum emission wavelength, emission intensity, or the shape of the profile that are caused by the presence of an in a sample may be used to determine the presence or concentration of the ion in the sample. Changes in excitation or emission spectra may be measured as ratios of two wavelengths. A range of changes are possible, from about a few nm to 5, 10, 15, 25, 50, 75, 100, or more nm.
Quantum yield may be obtained by comparison of the integrated area of the corrected emission spectrum of the sample with that of a reference solution. A preferred
reference solution is a solution of fluorescein in 0.1 N NaOH, quantum efficiency 0.95. The concentration of the reference is adjusted to match the absorbance of the test sample. The quantum yields may be calculated using equations known to those of skill in the art.
A change in quantum yield caused by an ion may be used as the basis for detecting the presence of the ion in a sample and may optionally be used to determine the concentration of the ion. A range of changes are possible. For example, the difference in the quantum yield for a subject sensor in the presence of a ion may be about 10%, 25%, 50%, 75% the quantum yield, or it may be 2, 3, 5, 10, 100, 200, 1000, or 10000 times greater or more. The same values may be used to describe changes observed in intensity in such the subject assays.
It is expected that some samples will contain compounds that compete with the sensor for the ion. In such cases, the fluorescence measurement will reflect this competition. In one variation, the fluorescence may be used to determine the presence or concentration of one or more such ion-competing compounds in a sample. In the case of potassium ion sensing, sodium ions are a common interfering ion for fluorescence measurements. The fluorescent sensing moieties provided herein, however, are largely unaffected by changes in pH and sodium ion concentration.
In some embodiments, the presence of potassium ion in a sample is detected by contacting the sample with a sensor as described herein. The fluorescence of the solution is then determined using one of the above-described devices, for example, a
spectrofluorometer. Optionally, the fluorescence of the solution may be compared against a set of standard solutions containing known quantities of the ion, e.g., potassium.
Comparison to standards may be used to calculate the concentration of the ion in the sample.
The analyte may be any described above (e.g., potassium ion, oxygen, or hydronium ion). The concentration of the analyte may change over time and the fluorescent signal of the sensor may serve to monitor those changes. For example, the particular form of the potassium ion that interacts with the sensor may be produced or consumed by a reaction occurring in the solution, in which case the fluorescence signal may be used to monitor reaction kinetics.
In some embodiments, a sensor as provided herein can be used to determine and quantitate the antibacterial qualities of a compound. Antibacterial compounds can stimulate a K+ efflux from the bacteria, which can be monitored through time dependent fluorescence intensity changes of the sensor. For example, a solution of a particular bacterium can be prepared in a medium (e.g., NaCl) in the presence of one or more sensing compounds. Upon addition of a candidate antibacterial compound, any K+ releasing from the bacteria into solution can be monitored through an increase in the fluorescence intensity of the sensor. The rate of K+ efflux can be used to observe and quantitate the antibacterial properties of the compound against the particular bacterium. See, for example, Example 23.
In certain embodiments, the sample is a biological fluid, lysate, homogenate or extract. The sample may contain one or more cells. Samples may have a pH of about 5, 6, 7, 8, 9, 10, 11, 12, or higher.
In another variation, the presence of an ion in a biological sample may be determined using a fluorescence microscope and one or more sensors described herein. The biological sample is contacted with the sensor and fluorescence is visualized using appropriate magnification, excitation wavelengths, and emission wavelengths. In order to observe co-localization of multiple analytes, the sample may be contacted with multiple sensors simultaneously. In certain embodiments the multiple sensors differ in their emission and/or excitation wavelengths.
Biological samples may include bacterial or eukaryotic cells, tissue samples, lysates, or fluids from a living organism. In certain embodiments, the eukaryotic cells are cancer cells, for example, folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells, or avp3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells.
Detection of an ion in a cell may include detection of the ion in subcellular or extracellular compartments or organelles. Such subcellular organelles and compartments include: Golgi networks and vesicles, pre-synaptic vesicles, lysosomes, vacuoles, nuclei, chromatin, mitochondria, chloroplasts, endoplasmic reticulum, coated vesicles (including clathrin coated vesicles), caveolae, periplasmic space and extracellular matrices. In some embodiments, the sensors used for intracellular detection can include a compound of
formula (1), (2A) or (3), polymers, random copolymers, or nanoparticles as described herein. Such intracellular measurements may be obtained by contacting the cell with a sensor as described above. In some embodiments, the sensor is contacted with the cell using microinjection.
Target compounds, polymers, and nanoparticles as described above may also be used to image a targeted cell in a patient. For example, the patient can be administered an effective amount of the desired targeted compound and imaged using suitable fluorescence techniques. Any cancer cell can be imaged if an appropriate targeting moiety is used. For example, folate receptor rich/over expressing cancer cell lines such as human cervical HeLa cells and human nasopharyngeal epidermal carcinoma KB cells can be imaged using a folic acid targeting group, or avp3-integrin rich cancer cell lines, such as human brain glioblastoma U87-MG cells can be imaged using a cRGD targeting group. Suitable fluorescence techniques for in vivo imaging can include a Xeneogen IVIS-200 System. Typically, such imaging will involve excitation of the fluorescent sensor using wavelengths of about 488 nm or longer to provide an emission spectrum in the green and red windows.
Detection of an ion in a fluid sample, for example, in the extracellular matrix of a biological sample, can be performed using an extracellular sensor such as those described above, or a compound of formula (2), such as:
and
Pharmaceutical Formulations and Dosage Forms
When employed as pharmaceuticals, the compounds, polymers, and nanoparticles described herein can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
This invention also includes pharmaceutical compositions which contain, as the active ingredient, a compound, polymer, or nanoparticle of the invention or a
pharmaceutically acceptable salt thereof, in combination with one or more
pharmaceutically acceptable carriers (excipients). When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, and sterile injectable solutions.
In preparing a formulation, an active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If an active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If an active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
The compounds, polymers, and nanoparticles described herein may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the active ingredient. The term "unit dosage forms"" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
In some embodiments, the compositions contain from about 5 to about 50 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 5 to about 10, about 10 to about 15, about 15 to about 20, about 20 to about 25, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 40 to about 45, or about 45 to about 50 mg of the active ingredient.
In some embodiments, the compositions contain from about 50 to about 500 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 50 to about 100, about 100 to about 150, about 150 to about 200, about 200 to about 250, about 250 to about 300, about 350 to about 400, or about 450 to about 500 mg of the active ingredient.
In some embodiments, the compositions contain from about 500 to about 1000 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 500 to about 550, about 550 to about 600, about 600 to about 650, about 650 to about 700, about 700 to about 750, about 750 to about 800, about 800 to about 850, about 850 to about 900, about 900 to about 950, or about 950 to about 1000 mg of the active ingredient.
Similar dosages may be used of the compounds described herein in the methods and uses of the invention.
The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the area
being imaged as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11 , more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
EXAMPLES
General Methods.
An amino-substituted triazacryptand ionophore (TAC-NH2) and an acetate- substituted triazacryptand ionophore (TAC-CHO), N-2-propenyl-4-bromo-naphthalimide (compound 1), and 2-dicyanomethylene-3-cyano-4,5,5-trimethyl-2,5-dihydrofuran (TCF) were synthesized according to known procedures (He, H. et al., J. Am. Chem. Soc. 2003, 125, 1468-1469; Konstantinova T.N. et al, J Appl Polym Sci 2M9;m \991-l99S; and Gopalan, P. et al., J. Am. Chem. Soc. 2004, 126, 1741-1747). Lysosensor SM3 was prepared according to our published procedure (Tian, Y. et al., Biomaterials 2010, 31, 7411-7422). HEMA, AM, METAC, trimethylsilylpropyl acrylate (TMSPA),
azobisisobutyronitrile (AIBN), Ν,Ν-diisopropylethylamine (DIPEA), N-methyl-2- pyrrolidone (NMP), amphotericin, KC1, NaCl, CaCl2, MgCl2, FeCl3, ZnCl2, CuCl2, 4-(2- hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES), nigericin, bumetanide, and ouabain were purchased from Sigma-Aldrich (St. Louis, MO). Hoechst 33342, PBFI, and MitroTracker® Green FM were ordered from Invitrogen (Carlsbad, CA).
A Varian liquid-state NMR operated at 400 MHz for 1H NMR and at 100 MHz for 13C MR was used for NMR spectra measurements. High resolution mass spectrometry (HRMS) was performed by the ASU Mass Spectrometry Laboratory. A Shimadzu UV-3600 UV-Vis-NIR spectrophotometer (Shimadzu Scientific Instruments,
Columbia, MD) was used for absorption spectra measurements. A Shimadzu RF-5301 spetrofluorophotometer was used for fluorescence measurements.
100 mg (138.53 μηιοΐ) of amine (compound I), 47.19 mg (149.27 μηιοΐ) of compound II, and 21.05 mg of N,N-diisopropylethylamine (DIPEA) were suspended in 1 mL N-methyl-2-pyrrolidone (NMP) and microwaved to 150 °C for 4 h. The mixture was poured into 10 mL water. The resulting precipitate was filtered and washed with 10 mL water. The crude product was then purified with silica gel column using
chloromethane/methanol to afford 36 mg (27.3%) of the desired compound as a yellow gum.
I
100 mg (138.53 μηιοΐ) of aldehyde (compound III; TAC-CHO), 2- dicyanomethylene-3-cyano-4,5,5-trimethyl-2,5-dihydrofuran (33.12 mg, 166.23 μηιοΐ; compound IV) and ammonium acetate (10.7 mg, 138.53 μηιοΐ) were dissolved in a mixture of 1 mL of THF and 5 mL of ethanol. The mixture was stirred for 8 h at room temperature. The products were collected by filtration and washed with ethanol and diethyl ether to obtain 71.2 mg of a red color compound. Yield: 56.9%.
The desired monomers (including monomeric compounds of formula (1) and (2A), monomers of compounds (D), monomers of compound (B, and monomers of compound (C) with controlled molar or weight ratios) and initiator (e.g., AIBN) will be dissolved in suitable solvent (e.g., DMF, DMSO, ethanol, or water). The mixture will be degassed a few times and filled with nitrogen. The polymerization will be carried out under the nitrogen condition and at 65 °C for a time sufficient to complete
polymerization (e.g., 24 hours). After polymerization, the polymer can be precipitated from the reaction mixture. The polymers can be further purified using dialysis approach.
Example 4. General methods for the preparation of nanoparticles
The desired monomers (including monomeric compounds of formula (1) and
(2A), monomers of compounds (D), monomers of compound (B, and monomers of compound (C) with controlled molar or weight ratios) and initiator (e.g., AIBN) will be suspended in water with a suitable surfactant (e.g., Tween 20 or SDS). After degassing using nitrogen flow, the polymerization will be carried out under the nitrogen condition and at 65 °C for a time sufficient to complete the polymerization (e.g., 24 hours). After polymerization, the formed nanoparticles will be purified using dialysis. The sizes of the nanoparticles will be characterized using dynamic light scattering (DLS) atomic force microscopy (AFM), scanning electron microscopy (SEM), or transmission electron microscopy (TEM).
Example 5. General methods for the preparation of sensing membranes for extracellular potassium ion sensing
Sensing films can be prepared either through thermal polymerization (using 4,4- azobis(4-cyanovaleric acid), azobisisobutyronitrile (AIBN) or benzoyl peroxide (BPO) as the thermal initiators) or using a photoinitiator, such as Benzophenone, Irgacure 851 (2,2- dimethoxyphenylacetophenone), or Irgacure 819 (bis(2,4,6-trimethylbenzoyl)- phenylphosphineoxide). A sensor as prepared in Example 1, a thermal polymerization initiator, and comonomers with a crosslinker for the matrix were dissolved in Ν,Ν'- dimethyl formamide (DMF). The DMF solution was added onto an acrylate-moiety functionalized quartz glass and the solution was covered with a clean cover slip
(untreated) to form a sandwich structure. Film thickness was controlled using a Kapton- type electric tape (typically 25 μιη thick, DuPont, Wilmington, DE). This was placed in a vacuum oven, which was then evacuated and refilled with nitrogen three times.
Polymerization was carried out under nitrogen at 80 °C for 1.5 hours. The quartz glass with a polymer film was removed from the oven, and the tape and cover slip were removed. The uniform polymer film on the quartz glass was then washed three times with
methanol, followed by three times with double-distilled water, to remove any non- polymerized monomers and the residual DMF. The films were dried and stored in the dark at room temperature.
This method was also used to prepare a dual sensing film for potassium ion and oxygen sensing. The above procedure was followed, except two sensing monomers, the potassium monomer from Example 1 and an oxygen monomer having the structure:
were used simultaneously. Example 6. Measuring sensor response in aqueous solution.
A solution of a sensor of Example 1 and Example 2 was prepared at a
concentration of 5 μηιοΙ/L in HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid) buffer was titrated with various potassium ion concentrations. Sensors of Example 1 were excited at 450 nm to generate its green emission (FIG. 2), and collected from 470 nm to 650 nm with a maximum at 520 nm. Sensors of Example 2 were excited at 488 nm to generate its red emission (FIG. 3) collected from 550 nm to 750 nm with a maximum at 650 nm. The response for each sensor is shown in FIGs. 2 and 3.
Example 7. Intracellular potassium ion sensing
Human glioblastoma U87-MG cells, Barrett's esophagus precancer small cell lung cancer (CPC) cells, and mouse macrophage RAW 264.7 cells were used to test the subcellular distributions of the potassium ion sensors of Example 1 and 2. After cells were cultured in 96 wells at 10,000 cells/well for 24 hours, the sensors (5 μηιοΐε/υ) were dissolved in DMSO and added into the cell culture medium. After a 30 minute
incubation, the subcellular distribution of the sensors was studied by using confocal fluorescence microscopy. Sensors were excited at 405 nm and typical emissions were collected from 515+15 nm for green emission and 605+37.5 nm for red emission. The fluorescent images are shown in FIGs. 4 and 5.
Example 8. Measuring extracellular sensing response in sensor films
The potassium ion sensing film prepared in Example 5 was immersed in a buffer and the emissions of the film were monitored upon the change of potassium ion concentration. Sensors were excited at 450 nm and typical emissions were collected from 470 nm to 650 nm for the green emission. The response of the film to varied
concentrations of potassium, sodium, and pH is shown in FIG. 6. As can be seen by the figure, the sensing film is specific for potassium and measures little interference from sodium, lithium, and cesium ion also present in solution. In addition, the sensing film is unaffected by changes in pH.
Example 9. Measuring oxygen and potassium ion response in a dual sensing film
A dual potassium and oxygen sensing film was prepared as described in Example 5. The sensing film was placed diagonally into quartz cuvettes containing buffers or cell culture medium. The sensors were excited at 440 nm to generate the green emission from the potassium ion sensor and the red emission of the oxygen sensor. Oxygen
concentration was adjusted by bubbling a nitrogen/oxygen gas mixture into the liquid contained in the cuvette. After the saturation of the liquid using the gas mixture with defined oxygen concentration, the emission spectra were taken. Potassium ion concentration in the solution was adjusted by tuning the concentrations of potassium chloride to measure the responses of the dual sensor film.
As shown in FIG. 7, no interference was observed between the potassium and oxygen sensors. Both sensors were able to detect and quantitatively measure their respective ions. Example 10. A method of synthesis of a compound of Formula (2): (2a)
In a round-bottom flask fitted with a reflux condenser, TAC-CHO (compound III; 100 mg, 138.5 μπιοΐ), and 2-dicyanomethylene-3-cyano-4,5,5-trimethyl-2,5-dihydrofuran (TCF; compound IV; 33.12 mg, 166.2 μηιοΐ) were dissolved in 2 mL of absolute ethanol. NaOH (2 mg) was added to this mixture and refluxed for 12 hrs. The deep violet solution was extracted with dichloromethane from water, and the organic layer was dried with MgS04. The crude product was purified by column chromatography over silica gel to get a dark-purple solid (62 mg, yield: 49.6%).
Example 11. Measuring quantum efficiency and sensor responses
The fluorescence quantum yields (η) of samples in solutions were recorded by using Rhodamine B in ethanol (η = 0.65) excited at 540 nm and were calculated according to the following equation; η5 are the
fluorescence quantum yields of standards and the samples, respectively. Ax and As are the absorbance of the standards and the measured samples at the excitation wavelength, respectively. Ix and 7S are the integrated emission intensities of standards and the samples, respectively. nt and ns are the refractive indices of the corresponding solvents present in the solutions, respectively. The experimental error was approximately 10%.
To determine sensor responses, 50 μΐ^ of 2(a) (Example 10) was dissolved in DMSO resulting in a concentration of 200 μΜ which was then added into 2 mL of HEPES (10 mM, pH 7.2) buffer. This resulted in a final 2(a) concentration of 5 μΜ in the buffer. Different metal ion concentrations were added into the solution for studying
2(a)'s responses. Although the reaction of the compound and the metal ion was rapid (usually within seconds), the spectra was measured after 2 minutes to ensure stability. 2(a)/metal ion complexes were excited at 561 nm and emissions were collected from 600 to 750 nm.
Data for 2(a) is shown in FIG. 8. Because of the strong derealization of electrons in the push-pull fluorophore in 2(a), the complex ability of the nitrogen atom of the aniline group, a component of the ligand for the potassium ion, decreased significantly. Such a decrease may result in a blunted binding ability of the whole ligand in the compound and decreased sensitivity of the intramolecular charge transfer (ICT) to the complexation with K+ to achieve a K4 of around one-tenth mole level.
2(a) is constructed using strong electron-donating (aniline) and electron- withdrawing (TCF) groups, yielding an absorption maximum at 560 nm. The extinction coefficient (έ) at 560 nm is 3.84 104 M_1 cm" . 2(a) displays weak fluorescence in its free form with a quantum yield (ή) of 0.11%. Upon addition of K+, the fluorescence intensity of 2(a) increases by ca. 4 and 50 fold at K+ concentrations of 140 mM and 1400 mM (FIG 8A and 8B), respectively, resulting in corresponding η of 0.52% and 5.6%. Kj was determined by the Benesi-Hildebrand equation:
F0/(Fo-F) = F0/(Fo-Fcom≠ex) + F0/(F0-Fcomplsx) x Kd x 1/[M] (1)
where FQ is the integrated fluorescence intensity of a free sensor, F is the observed integrated fluorescence intensity, -Fcompiex is the emission of the ligand-metal ion complex, and [M] is the metal ion concentration. When FQ/(FO - F) is plotted against 1/[M], the binding constant is given by the ratio intercept/slope. Curve fitting of 2(a) fluorescence intensity against the reciprocal of the K+ concentration (1/[K+]), this Benesi- Hildebrand plot yields a linear fit (FIG. 8C), where the Kd was estimated to be 88 mM. The linear fit evidences a 1 : 1 complexation behavior.
2(a) was also tested against physiological concentration levels of the following metal ions: K+, Na+, Ca2+, Mg2+, Fe3+, Zn2+, Mn2+, and Cu2+. The results revealed that the potassium ion had the greatest influence on the sensor's emissions (FIG. 8D).
Furthermore, this trend was also present when the concentrations of Na+, Ca2+, and Mg2+ were increased to 140 mM (FIG. 9). These results showed the high selectivity of 2(a) to K+. 2(a) was not sensitive to pH in the range of 5 to 8. The high selectivity to K+ with a
large Kj suggested that 2(a) is useful for intracellular sensing in a wide range of biological condition.
Example 12. Cell culture for imaging and subcellular distribution of the sensor U87MG cells (American Type Culture Collection, ATCC, Manassas, VA) were cultured in Eagle's minimum essential medium (EMEM) supplemented with 10% fetal bovine serum, 100 μ/mL penicillin, 2 mM L-glutamine (Sigma- Aldrich), and incubated at 37 °C in 5% C02 atmosphere. Cells were then seeded onto 96 well plates at 10,000 cells per well, and incubated for 1 day at 37 °C. CP-A cells (kindly provided by Dr. Brian J. Reid at Fred Hutchison Cancer Research Center, Seattle, WA) were cultured in
Keratinocyte-serum free medium (Invitrogen, Carlsbad, CA) supplemented with Bovine Pituitary Extract (BPE) and human recombinant Epidermal Growth Factor (rEGF, Invitrogen) at 37 °C in a 5% C02 atmosphere. Cells were seeded onto 96 well plates at 10,000 cells per well, and incubated for 1 day. Sensors dissolved in DMSO were added to the medium to make the sensor concentrations in a range of 0.5 - 5 μΜ. 10 min of internalization was found to be sufficient for achieving satisfactory images. To achieve images with satisfactory signal-to-noise ratio, a sensor concentration of 4 μΜ was usually used for intracellular study.
A study was conducted to test whether or not the sensor had specific subcellular distributions in cells: cells were co-stained using the sensor in combination with Hoechst 33342, Lysosensor SM3, and MitoTracker® Green FM, respectively. To co-stain the nuclei, Hoechst 33342 was used. Cells were first internalized with 2(a) (4 μΜ in cell culture medium) for 10 minutes. After removing medium and washing the cells with fresh medium, Hoechst 33342 dissolved in the fresh medium and was then added into the wells to stain cell nuclei for 30 min at 37°C. In order to co-stain the cell's mitochondria, MitoTracker® Green FM was used. The cells were treated in the same manner as the Hoechst staining method, but with a MitoTracker® Green FM in DMSO solution. To co- stain the lysosomes, Lysosensor SM3 was used. Again the cells were treated using the previously stated protocol while using a SM3 in DMSO solution. The resulting concentrations of Hoechst 33342, MitoTracker® Green FM, and Lysosensor SM3 in the cell medium were 10 μΜ, 50 nM, and 2 μΜ respectively.
Under a Nikon Eclipse TE2000E confocal fluorescence microscope (Melville, NY), Hoechst 33342 was excited at 405 nm and its blue emission was collected using a 450/35 nm filter set. Sensor (1(a)) was excited at 440 nm and the green emission was collected using a 515/30 nm filter set. Sensor (2(a)) was excited at 561 nm and its red emission was collected using a 605/75 nm filter set. Lysosensor SM3 was excited at 405 nm and its green emission was collected using a 515/30 nm filter set. And MitoTracker® Green FM was excited at 488 nm and its green emission was collected using a 515/30 nm filter set.
There are some co-localizations of 2(a) with mitochondria and lysosome, since the mitochondria and lysosome also contain potassium ions. These results indicated the non-specific cellular distribution of the potassium ion sensor, 2(a). The non-specific distribution of 2(a) indicated that it can be used to monitor potassium ions in the cytoplasm and in any of these compartments. Example 13. Cytotoxicity
Cytotoxicity of 2(a) to human glioblastoma U87MG cells was studied using Trypan blue staining. To cell culture medium (100 μΕ) with eukaryotic cells in a 96 well microplate with 10,000 cells/well that had internalized 2(a) for 2 hours, 10 mL of 0.4% Trypan Blue stain was added and mixed thoroughly with the medium. After standing for 5 min at room temperature (23 °C), the cells were imaged using an optical microscope in bright field mode. Dead cells appeared blue from the Trypan Blue stain, whereas healthy cells appeared transparent as a result of the cell's resistance to stain. The cells were then counted and the ratio of dead cells to live cells was calculated. Each experiment was repeated three times.
After internalizing the sensor with cells for 2 hours, more than 97% of the cells were viable, showing the non-cytotoxicity of 2(a) to U87MG cell line under our experimental conditions. Confocal images of U87MG cells internalized with 2(a) showed that 2(a) could be taken up by cells within 10 minutes. Red fluorescence was observed in the cytoplasm area, which was further confirmed by a minimum colocalization with blue emission from the nucleic staining probe (Hoechst 33342) (FIG. 10). Furthermore, the sensor did not have a specific colocalization in mitochondria or lysosomes, showing that
2(a) has a non-specific distribution and will therefore monitor potassium ions in the cytoplasm and in any of these compartments (FIG. 11 and 12).
Example 14. Monitoring the intracellular K+ efflux using 2(a)
To monitor the stimuli-response of the intracellular K+ level, cells internalized with 4 μΜ of 2(a) for 10 minutes were treated with a mixture of nigericin, bumetanide, and ouabain (FIG. 13) at 37°C. Specifically, U87MG cells were seeded onto 96 well plates at 10,000 cells per well in 100 \L medium overnight at 37°C. On the following day, the cells were internalized with 2(a) (4 μΜ) for 10 min at 37°C. A mixture of nigericin, bumetanide, and ouabain was then added. Final concentrations of nigericin, bumetanide, and ouabain in the cell culture medium were 5 μΜ, 10 μΜ, and 10 μΜ, respectively. Fluorescence in cells was visualized by Nikon Eclipse TE2000E confocal fluorescence microscope (Melville, NY) at 37 °C.
The decrease of the fluorescence intensities indicated the efflux of the
intracellular K+ from cells (FIG. 13a, 13c, and 13e). The combination of the ionophore nigericin with influx inhibitors of bumetanide (inhibitor of Na+, K+, 2Cr-cotransport) and ouabain (inhibitor of Na+, K+, ATPase pump) is an effective K+-efflux stimulator. This mixture effectively induced K+ efflux as shown in fluorescence images (FIG. 13).
Meanwhile, cell shrinkage with a preservation of an intact plasma membrane was observed after 60 mins of stimulation. It has been known that depletion of intracellular K+ will result in cell shrinkage, activated caspases, and DNA fragmentation, all of which are features of apoptosis. Therefore, the phenomenon observed in FIG. 13 indicated that U87MG cells underwent the apoptotic change through the K+ efflux induced by nigericin, ouabain, and bumetanide. A control experiment without the drug stimulation did not show obvious fluorescence intensity changes or morphological shrinkages.
Example 15. Monitoring the intracellular K+ influx using 2(a)
2(a) can also be used to monitor K+ influx through stimuli. U87MG cells were seeded onto 96 well plates at 10,000 cells per well in 100 iL medium overnight at 37°C. On the following day, the cells were internalized with 2(a) (4 μΜ) for 10 min at 37°C.
The influx stimulator (isoproterenol in KCl-containing PBS buffer) was added. Final
concentrations of the added isoproterenol and KCl in the cell culture medium were 5 μΜ and 20 mM, respectively. Fluorescence in cells was visualized by Nikon Eclipse
TE2000E confocal fluorescence microscope (Melville, NY) at 37 °C.
Internalization with 2(a) only induced a slight fluorescence intensity increase, while obvious fluorescence increase was observed after cells were treated with 5 μΜ isoproterenol and the 20 mM KCl in medium for 40 minutes at 37°C (FIG. 14).
Isoproterenol was reported to be a potassium ion influx stimulator by stimulating cyclic adenosine monophosphate (cAMP) generation, which associates with physiology change in K+ transport. The average fluorescence intensity of cells after the treatment was 33% greater than that before the treatment; which was quantified using Image J software - a public domain developed at the National Institute of Health.
Example 16. Dynamic potassium ion influx and efflux
2(a) was further tested for in-situ observation of dynamic potassium ion influx and then efflux through the changes of fluorescence (FIG. 15) stimulated by an ionophore nigericin. Cells internalized with 4 μΜ of 2(a) at 37 °C for 10 minutes were washed with 20 mM KCl-containing fresh medium. Nigericin (20 μΜ at its final concentration) was added in 20 mM KCl-containing medium to help K+ to across cell membrane. Enhanced fluorescence was immediately observed after the addition of nigericin, indicating potassium ion influx occurred. The potassium influx peaked after 3 minutes with an average of fluorescence increase of 370%. After 3 minutes, potassium efflux was observed by the decrease of the fluorescence. The efflux stabilized after 15 minutes, and the fluorescence intensity after the stabilization was about 25% below that of before the stimulation by nigericin. The ionophore nigericin was used to stimulate K+ influx for yeast Saccharomyces cerevisiae. 11 was also reported to be a K+ efflux stimulator for human colorectal adenocarcinoma HT-29 cells. The observation of the K+ influx and then efflux of U87MG cells using 2(a), demonstrating its further utility in measuring the kinetic of K+ transport. Example 17. Interference of benzofuran isophthalate (PBFI) on 2(a) uptake
For this comparison, two independent experiments were carried out. In the first experiment, cells were internalized with 2(a) for 10 minutes at a concentration of 2 μΜ at 37 °C for 10 minutes. Then the medium containing the sensor was removed, and new medium was added for imaging at 37 °C. While in the second experiment, the cells were first internalized with PBFI at a concentration of 10 μΜ in cell culture medium for 30 minutes at 37°C. Then 2(a) (at a concentration of 2 μΜ) was added to the cell medium. Cells were further incubated at 37 °C for 10 minutes. After which the sensor and medium were removed, and new medium was added for imaging at 37 °C. The excitation wavelength was 561 nm and the emissions were collected using a 605/75 nm filter set. Both of the experiments were carried out using the same optical procedure.
Example 18. Synthesis of a compound of Formula (1): 1(a)
(135.7 umol) of TAC-N¾, 51.5 mg (149.27 umol) of compound 1, and 21.1 mg of DIPEA were suspended in 1 mL NMP and microwaved to 150 °C for 4 h. The mixture was poured into 10 mL water. The resulting precipitate was filtered off, and then washed with 10 mL water. The crude product was purified using a silica gel column to yield 36 mg yellow gum. Yield: 27.3%. Example 19. Typical procedure for extracellular sensing film preparation.
Thin films were prepared according to our published protocols (Tian Y. et al., Biomaterials 2010; 31 :7411-7422; and Tian Y. et al, Chem Mater 2010; 22:2069-2078). A schematic drawing of the film preparation is given in FIG. 16. F4 film is described as a typical example. The components of other films are given in Table 1.
Table 1. Compositions of the films Fl to F8, their sensitivity, and values.
Films Polymer compositions and their Sensitivity (F/F0) b) Xd (mM) weight ratios a)
Fl PAM 1.02 (± 0.01) N/A
F2 PHEMA 1.77 (± 0.03) 18.5
F3 PHEMA:PAM (50:40) 2.03 (± 0.03) 14.9
F4 PHEMA:PAM (80:15) 2.34 (± 0.02) 7.25
F5 PHEMA:PAM:PMETAC 1.59 (± 0.02) 26.3
(80:15:20)
F6 PHEMA:PAM:PMETAC (80:15:5) 1.90 (± 0.02) 15.8
F7 PHEMA:PAM:PMESA (80:15:5) 2.69 (± 0.03) 6.04
F8 PHEMA:PAM:PMESA (80:15:20) 3.03 (± 0.03) 4.96 a) Each film contains a 5%-weight percent SR454 crosslinker. b) The sensitivity of the sensing films to + was at the 0 and 10 mM KCl conditions for comparison because this range is usually enough for extracellular K+ sensing. F0 is the fluorescence intensity before the titration using KCl. F is the fluorescence intensity at 10 mM KCl.
1 mg of the monomelic 1(a), 800 mg of HEMA, 150 mg of AM, 50 mg of SR454, and 10 mg of AIBN were dissolved in 1 mL DMF as a stock solution. 15 μΕ of the stock solution was added onto the surface of the TMSPA-modified quartz glass and covered with a clean but untreated cover slip to make a sandwich structure. Using TMSPA to modify the quartz glass was to enable the sensors and matrices to be chemically grafted onto a quartz substrate (Tian Y, et al., Chem Mater 2010; 22:2069-2078). The thickness was controlled using 25 μηι Kapton tape (DuPont, Wilmington, DE). The sandwich set-up was placed into a vacuum oven, which was then evacuated and refilled with nitrogen three times. Polymerization was carried out under nitrogen at 80 °C for 1.5 h in the oven. The quartz glasses with polymer membranes were removed from the oven, then the Kapton tape and non-surface modified glass was removed from the polymerized membrane surface. The polymerized membranes on the quartz glasses were washed three times with methanol to remove any remaining non-polymerized monomers and residual DMF. The films were dried and stored away from light at room temperature. The sensing films were stable in water for at least 3 months without any leaching of the sensing moieties or change hi sensing performance.
Example 17. Culture of E. coli and B. subtilis for potassium release study.
E. coli JM 109 and B. subtilis 168 were cultured overnight in LB medium
(Difco®, Becton, Dickinson and Company, Sparks, MD) by shaking at 180 rpm at 37 °C. The concentration of E. coli and B. subtilis in culture was estimated by measuring the optical density at 600 nm (OD60o)- OD60o value of 1 indicated a concentration of 5.0 χ 10 cfu/mL. After the microorganism density was determined, bacterial cells were collected by centrifuge at 2000 x g for 20 minutes at room temperature. Then appropriate densities of bacteria were made using fresh buffer (150 mM NaCl, pH 7.4) to achieve the desired initial concentrations for experiments.
The F4 film (Example 16) was placed diagonally into quartz cuvettes with 2 mL of bacteria suspension at different densities. Potassium release from the bacteria was stimulated by adding 100 of 20 mg/mL lysozyme. Emission measurements were taken every 5 min at the sensor's peak emission (525 nm) using an excitation wavelength of 450 nm. The potassium ion concentration was calculated from the measured fluorescence ratio (F/FQ).
Example 18. Sensing performance of 1(a) in buffer.
FIGs. 17A and 17B show the UV-Vis and emission spectral changes upon the interaction of 1(a) with potassium chloride (KC1) in 10 mM HEPES buffer (pH 7.4). The absorption spectra before and after interaction with K+ did not change, while emission intensities increased with increasing K+ concentrations. This fluorescence change was attributed to photo-induced electron transfer. The lone electron pairs of the amino groups in the triazacryptand ligand quench the emission of the fluorophore of the amino- naphthalimide through PET. After interaction with K+, the lone electron pairs of the ligand were occupied due to the formation of the ligand-K+ complex. This change restores the emission of the amino-naphthalimide fluorophore. Fluorescence intensity change at 525 nm was plotted again K+ concentration, which is illustrated in FIG. 17C. Binding constant K could be determined by the fluorescence spectral change using the Benesi-Hildebrand equation as described above.
Curve fitting of the fluorescence intensity of 1(a) against the reciprocal of the K+ concentration (1/[K+]), the Benesi-Hildebrand plot, gives a linear fit (FIG. 17D). This is a
characteristic of a 1 :1 complexation behavior from which the binding constant (X) is estimated to be 0.133 mM"1, corresponding to the disassociation constant (¾) of 7.53 roM.
1(a) shows a high selectivity against a few biologically relevant metal ions (FIG. 17E) including Na+. Na+ is usually an interference ion to K+ for the typical K+ probes including PBFI, CD 18, CI 8, and MCC.
Example 19. Monitoring the intracellular K+ efflux using 1(a).
U87MG and CP-A cells were seeded onto 96 well plates at 10,000 cells per well and maintained in 100 iL medium overnight. The following day, the cells were loaded with 1(a) (2 μΜ) for 20 min, then the excess 1(a) was removed by washing with medium. The test substances were added and the experiment was terminated after 2.5 h by washing the cells with physiological NaCl solution. A microplate reader (Molecular Device, Downingtown, PA) was used to read the fluorescence intensities from the intracellular 1(a). 444 nm was used to excite the sensor and the emission was measured at 538 rrm. The measured fluorescence intensities were corrected with background fluorescence. Each experiment was repeated in triplicate.
Example 20. Sensing performances of 1(a) in the membranes of Fl to F8.
Typical K+ sensing using film F4, made of PHEMA-co-PAM with 80: 15 by weight, is shown in FIG. 18. FIG 18A shows the emission change upon titration with KC1. Its corresponding fluorescence intensities at 525 nm were given in FIG. 18B. The sensing response to Na+ was also given in FIG. 18B, showing the high selectivity of K+ to Na+. This trend is in accordance with that of pure 1(a) in buffer. However, the sensitivity of this sensing film F4 is better than that of pure 1(a), which may possibly be due to the fact that this sensing film can be swollen by water, resulting in a better interaction of the sensing moiety in the PHEMA-co-PAM hydrogel with K+. Curve fitting of the fluorescence intensity of F4 against the reciprocal of K+ concentration (1/[K+]) using the Benesi-Hildebrand equation 1 gives a linear fit (FIG. 18C). This suggests the
characteristic of a 1 : 1 complexation behavior from which the association constant (K is
estimated to be 0.138 mM"1, corresponding to the disassociation constant (i¾) of 7.25 mM.
For K+ sensors, besides the interference by Na+, pH value is another factor to be concerned. FIG. 18D plots the pH dependent fluorescence changes at different pH values. Results showed that this sensing membrane before the complexation with K+ had no response to pH from 6 to 8. After the complexation with the K+, the sensing membrane did not respond to pH from 5 to 8. These results are in accordance with other K+ sensors derived from the triazacryptand ligand. These results showed our K+ sensors are minimally influenced by biological pH values.
FIG. 19 gives the comparison of the responses of the eight thin films to K+. The sensing membrane made of PAM matrix (Fl) did not response to K+, indicating its poor K+ permeability. Sensing membrane F2 made of PHEMAhas better response to K+ than that of Fl. Interestingly, the two films of F3 and F4 show much better sensitivity than F2, indicating the chemical composition of the PFTEMA-c -PAM improves K+ permeability. It is known that PHEMA can have good swelling properties and ion permeability.
However, its swelling and ion permeability could be further improved by the
copolymerization with other water soluble polymers, such as PAM. The composite materials can increase the swelling degree (W∞) and therefore increase the range of pore sizes and size distribution in the hydrogel film. To our knowledge, this is the first study of matrix influence on potassium ion sensitivity of a K+ probe
Charges of polymers also affect the sensing activities of sensing films. Increasing the density of negative charge on the film by MESA obviously improved the sensitivity of K+ response. In contrast, increasing the density of positive charge by METAC decreased the response sensitivity to K+. At present the detailed mechanism is not completely understood, but it is believed to be related to the ion permeability of the matrix and the water swelling properties of the various composite materials.
The above studies demonstrate that by taking the advantages of the polymerizable vinyl group, different sensing membranes could be prepared through the tuning of the structures of monomeric precursors for matrices and their composited ratios. Through the tuning of the chemical composites, the sensing performances were also manipulated.
Example 20. Demonstration of the applicability of 1(a) for intracellular sensing.
Two cell lines (U87MG and CP- A) were used for intracellular sensing. It is well known that cells usually contain about 150 mM of K+, which is within the sensing range of 1(a). FIG. 20 shows the confocal fluorescence images of 1(a). 1(a) can internalize with cells within a short time, as few as 10 minutes. A 1(a) concentration of 0.5 μΜ in cell culture medium was able to stain cells, but the signal was weak. To achieve images with satisfactory signal-to-noise ratios, a sensor concentration of 2 μΜ was used for intracellular study. Bright green fluorescence was not uniform throughout the cells, implying the nonuniform K+ distribution of the intracellular K+ in the cytoplasm area. The subcellular distribution of the sensor in the cytoplasm region was further confirmed by a minimum colocalization of the green emission of 1(a) with blue emission from the nuclear staining probe (Hoechst 33342). For intracellular sensing, a significant concern is whether the sensor is affected by the intracellular pH value, especially the low pH value (around 4.5 to 5.5) of the lysosome. To assess this, cells were co-stained with 1(a) and LysoTracker Red®, which is a specific staining reagent for lysosome with red emission. Only minimum overlay of the green emission from 1(a) with red emission from LysoTracker Red® was observed from the yellow color, indicating 1(a) responds to K+, rather than pH. This could be attributed to 1(a) not responding to biologically relevant pH values. Therefore, 1(a) has been demonstrated as a good K+ sensor for intracellular potassium ion imaging.
Example 21. Cytotoxicity.
Cytotoxicity of the sensor 1(a) to cells was studied using Trypan blue staining. After 30 minutes internalization of the sensor with cells, more than 97% cells were viable, showing the non-cytotoxicity of 1(a) to the two cell lines under our experimental conditions.
Example 22. Stimuli responsive change of the intracellular K* level.
To monitor the stimuli-responsive change of the intracellular K+ level, cells internalized with 2 μΜ 1(a) for 20 minutes were treated with ATP, nigericin (Nig), amphotericin B (Ampho B), and a mixture of nigericin, bumetanide, and ouabain (FIG.
21). The decrease of the fluorescence intensities indicates the efflux of the intracellular potassium ions from the cells. ATP is stimulating molecule of ATP-gated K+ channels. Amphotericin B (AmphoB) is an efflux stimulator. Nigericin is an ionophore. The relative percentages of the fluorescence intensities before and after the addition of the stimuli materials are given in FIG. 21. It was found that nigericin ionophore was not an efficient K+ efflux stimulator. However, the combination of the ionophore with influx inhibitors bumetanide (B) (inhibitor of Na+, K+, 2Cl"-cotransport) and ouabain (O) (inhibitor of Na+, K+, ATPase pump) has been shown to induce an obvious K+ efflux in the two cell lines. These results are in accordance with the trends of other studies.
Therefore, 1(a) was demonstrated to be a new candidate for the monitoring of intracellular potassium ion balance.
Example 23. Application of the K+ sensing films for studying antimicrobial reagents.
F4 film was used for both gram positive (i.e. B. subtilis) and negative (i.e. E. coli) bacteria and lysozyme was used as a model drug to stimulate K+ efflux from the organisms. The bacteria were cultured at 37 °C overnight, centrifiiged, and washed three times with potassium-free buffer with 150 mM NaCl at pH of 7.4. The washed organisms were resuspended in 2 mL of the potassium-free buffer in quartz cuvettes at a
concentration range of 1.5 * 1010 to 1.0 x 1011 cfu/mL. F4 was immersed into the above prepared mixtures, and then lysozyme was added into the cuvettes to stimulate the K+ efflux, which was monitored through the time dependent fluorescence intensity changes of F4 film. With the K+ releasing from the bacteria into the NaCl solution, the fluorescence intensity of F4 increases. FIG. 22 plots the time and bacterial concentration- dependent K+ concentration changes measured by using F4 film. For E. coli, + efflux increased slowly over time; while for B. subtilis, K+ efflux was very fast, within the first 10 minutes, and then very slow within the rest of time course. The difference between E. coli and B. subtilis is due to the antibacterial properties and action mode of lysozyme, which is more facile and faster in B. subtilis (gram-positive bacteria) compared to E. coli (gram-negative bacteria). The bactericidal properties of lysozyme are primarily ascribed to its N-acetylmuramoyl hydrolase enzymatic activity, resulting in peptidoglycan
hydrolysis and cell lysis. Gram-negative bacteria are relatively insensitive to lysozyme by the virtue of their outer membrane that acts as a physical barrier preventing access of the enzyme. A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
Claims
WHAT IS CLAIMED IS:
1. A compound having the formula:
or a salt form thereof,
wherein:
m is 0 or 1 ;
n is an integer from 0 to 3; and
X is selected from the group consisting
2. The compound of claim 1, wherein the compound is selected from the group consisting of:
or a salt form thereof. A compound having the formula:
wherein:
Z is selected from the group c
n is an integer from 0 to 3;
X is selected from the group consisting of:
H,
4. The compound of claim 3, wherein the compound is selected from the group consisting of:
84
85
5. The compound of claim 3, wherein the compound is selected from the group consisting of:
or a salt form thereof. The compound of claim 3, wherein the compound is selected from the group consisting of:
or a salt form thereof. 7. A random copolymer comprising:
from about 0.01 to about 10% by weight A;
from about 10 to about 90% by weight B;
from about 10 to about 90%> by weight C;
A is a compound of claim 1 or 3;
B is a biocompatible polymer; and
C is a targeting group. 8. The copolymer of claim 7, wherein the sum of A, B, and C is 100% by weight of the copolymer.
9. The copolymer of claim 7, wherein B comprises a biocompatible polymer selected from the group consisting of: dextran, chitosan, glycol chitosan, poly-L-lysine, poly- aspartic acid, PEG and derivatives thereof, poly(amino acid)s, poly(N-isopropyl acrylamide) (PNIPAAm), poly(dimethylamnioethyl methacrylate) (PDMEM), poly(aminoethyl methacrylamide) (PAMEM), poly[(N-2-hydroxypropyl) methacrylamide] (PHPMA), polyacrylamide, poly(2-hydroxyethyl methacrylate), poly(2-methacryloxyethyl sulfonic acid), poly(methacryloxyethyl trimethyl ammonium chloride), poly( vinyl pyridine), and poly[poly(ethylene glycol) methacrylate]. 10. The copolymer of claim 7, wherein B is selected from the group consisting of:
^~^0(CH2CH20)NH ^^OCH2CH2N(CH3)2
wherein each n is independently an integer from 0 to 30. 11. The copolymer of claim 7, wherein C comprises a targeting group selected from the group consisting of: polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. 12. The copolymer of claim 11 , wherein C further comprises a linking group. 13. The copolymer of claim 7, wherein C is selected from the group consisting of:
14. The copolymer of claim 7, wherein the copolymer further comprises from about 10 to about 100% by weight D, wherein D is a fluorescent oxygen sensor.
15. The copolymer of claim 14, wherein the sum of A, B, C, and D is 100% by weight of the copolymer.
16. The c the formula:
or a salt form thereof,
wherein:
M is Pt or Pd;
RLS R2, R3, P , R5, and R^ are independently selected from the group consisting of: H, F, CI, Br, I, CH3, OCH3, and OC2¾;
R7, R8, R9, and R10 are independently selected from the group consisting of:
(CH2)nOH, 0(CH2)nOH, NH(CH2)nOH, (CH2)nOW, 0(CH2)nOW, NH(CH2)nOW, (OCH2CH2)nOH, NH(CH2CH20)nH, (OCH2CH2)nO , NH(CH2CH20)nW;
n is an integer from 0 to 10.
The copolymer of claim 16, wherein D
18. A nanoparticle comprising polymerized monomers of claim 1 or 3. 19. The nanoparticle of claim 18, wherein the monomers are polymerized in a random copolymer. 20. The nanoparticle of claim 18, wherein the diameter of the nanoparticle is within the range of about 1 ran to about 300 run. 21. The nanoparticle of claim 18, wherein the nanoparticle further comprises
polymerized monomers of a targeting group.
22. The nanoparticle of claim 21, wherein the monomers are polymerized in a random copolymer. 23. The nanoparticle of claim 21 , wherein the targeting group is selected from the group consisting of polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. 24. The nanoparticle of claim 23, wherein the targeting group is selected from folic acid and cRGD. 25. The nanoparticle of claim 21 , wherein the monomers of the targeting group are selected from the group consisting of:
7/ OCH2CH2N(CH3)2 NHCH2CH2NH-Folic acid
26. The nanoparticle of claim 18, wherein the nanoparticle further comprises
polymerized monomers of a fluorescent oxygen sensor, a fluorescent pH sensor, or a combination thereof. 27. The nanoparticle of claim 26, wherein the monomers are polymerized in a random copolymer. 28. The nanoparticle of claim 18, wherein the nanoparticle further comprises
polymerized monomers of a biocompatible polymer selected from the group consisting of: dextran, chitosan, glycol chitosan, poly-L-lysine, poly-aspartic acid, PEG and derivatives thereof, poly(amino acid)s, poly( V-isopropyl acrylamide)
(PNIPAAm), poly(dimethylamnioethyl methacrylate) (PDMEM), poly(aminoethyl methacrylamide) (PAMEM), poly[(N-2-hydroxypropyl) methacrylamide] (PHPMA), polyacrylamide, poly(2-hydroxyethyl methacrylate), poly(2-methacryloxyethyl sulfonic acid), poly(methacryloxyethyl trimethyl ammonium chloride), poly(vinyl pyridine), and poly[poly(ethylene glycol) methacrylate]. 29. The nanoparticle of claim 28, wherein the monomers are polymerized in a random copolymer. 30. The nanoparticle of claim 28, wherein the monomers of the biocompatible
wherein each n is independently an integer from 0 to 30. 31. The nanoparticle of claim 18, wherein the monomers are polymerized in a random copolymer comprising:
from about 0.01 to about 10% by weight A;
from about 10 to about 90% by weight B;
from about 10 to about 90% by weight C;
wherein:
A is the compound of claim 1 or 3;
B is a biocompatible polymer; and
C is a targeting group.
32. The nanoparticle of claim 31 , wherein the sum of A, B, and C is 100% of the weight of the random copolymer. 33. The nanoparticle of claim 18, wherein the monomers are polymerized in a random copolymer comprising:
from about 0.01 to about 10% by weight A;
from about 10 to about 90% by weight B;
from about 10 to about 90% by weight C; and
from about 0.01 to about 10% by weight D;
wherein:
A is the compound of claim 1 or 3 ;
B is a biocompatible polymer;
C is a targeting group; and
D is a fluorescent oxygen sensor, a fluorescent pH sensor, or a combination thereof. 34. The nanoparticle of claim 33, wherein the sum of A, B, C, and D is 100% by weight of the copolymer. 35. A polymer thin film, wherein the polymer comprises a polymerized monomer selected from claim 1 or 3. 36. The polymer thin film of claim 35, wherein the thin film is formed on a substrate. 37. The polymer thin film of claim 36, wherein the substrate is selected from the group consisting of: glass, transparent polymer, and transparent copolymer polymeric mixture. 38. The polymer thin film of claim 36, wherein the substrate is selected from the group consisting of plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2-
hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof. 39. The polymer thin film of claim 36, wherein the substrate is an organic or
inorganic glass. 40. The polymer thin film of 39, wherein the glass is quartz glass. 41. The polymer thin film of claim 36, wherein the substrate is an optic fiber bundle. 42. The polymer thin film of claim 35, wherein the thickness of said polymer thin film is from about 0.1 to about 100 μηι. 43. A sensing film comprising a substrate covalently bound to a compound of claim 1 or 3. 44. The sensing film of claim 43, wherein the compound is covalently bound to the substrate through a linker. 45. The sensing film of claim 43, wherein the substrate is selected from the group consisting of: glass, transparent polymer, transparent co-polymer or polymeric mixture. 46. The sensing film of claim 43, wherein the substrate is selected from the group consisting of plasticized or non-plasticized poly(vinyl chloride) (PVC), sol-gel materials, polyvinylformal-silica mixtures, hydrogels, polyurethanes, poly(2- hydroxyethyl methacrylate), polyacrylamide, polydimethylsiloxane, polyethylene terephthalate, polystyrene, and mixtures thereof. 47. The sensing film of claim 43, wherein the substrate is an organic or inorganic glass.
48. The sensing film of claim 47, wherein the glass is quartz glass.
49. The sensing film of claim 43, wherein the sensor further comprises a fluorescent oxygen sensor, a fluorescent pH sensor, or mixtures thereof.
50. A targeted compound having the formula:
or a salt form thereof,
wherein:
Z is selected from the group consisting
m is 0 or 1 ;
n is 0 or 1 ;
L is a linker; and
Y is a targeting group. 51. The mpound has the formula:
or a salt form thereof,
wherein:
m is 0 or 1 ;
L is a linker; and
Y is a targeting group. 52. The targeted compound of claim 50, wherein the targeting group is selected from the group consisting of: polypeptides, antibodies, receptor ligands, carbohydrates, lipids, folic acid, hormones, growth factors, antigens, aptamers, chlorotoxin, and nucleic acids. 53. The targeted compound of claim 52, wherein the targeting group is selected from the group consisting of: folic acid, cyclo(arginine-glycine-aspartic acid) (cRGD), TAT peptides, and galactose. 54. The targeted compound of claim 50, wherein the compound is selected from the group consisting of:
55. A method of measuring potassium ion concentration in a sample, the method comprising contacting the sample with a compound of claim 1 , 3, or 50 and measuring the fluorescence emitted by the compound. 56. The method of claim 55, wherein the sample is a fluid sample. 57. The method of claim 56, wherein the sample comprises one or more cells. 58. The method of claim 55, wherein the potassium ion concentration is measured in the extracellular fluid of the sample. 59. The method of claim 55, wherein the potassium ion concentration is measured in the intracellular fluid of the cells. 60. A method of measuring potassium ion concentration in a cell, the method
comprising contacting the cell with a compound of claim 1, 3, or 50 and measuring the fluorescence emitted by the compound. 61. The method of claim 60, wherein the measuring is by spectrofluorimetry.
62. The method of claim 60, wherein the cell is a cancer cell. 63. The method of claim 60, wherein the compound is contacted with the cell using microinjection. 64. The method of claim 60, wherein the compound is a polymerized monomer in a polymer thin film. 65. The method of claim 60, wherein the compound is covalently attached to a surface. 66. The method of claim 60, wherein the compound is a polymerized monomer in a nanoparticle. 67. A method of imaging a cancer cell in a patient, the method comprising
administering to the patient an effective amount of a compound of claim 1, 3, or 50 and imaging the patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/985,260 US9181375B2 (en) | 2011-02-14 | 2012-02-13 | Fluorescent potassium ion sensors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161442518P | 2011-02-14 | 2011-02-14 | |
US61/442,518 | 2011-02-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012112440A2 true WO2012112440A2 (en) | 2012-08-23 |
WO2012112440A3 WO2012112440A3 (en) | 2012-11-22 |
Family
ID=46673101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/024856 WO2012112440A2 (en) | 2011-02-14 | 2012-02-13 | Fluorescent potassium ion sensors |
Country Status (2)
Country | Link |
---|---|
US (1) | US9181375B2 (en) |
WO (1) | WO2012112440A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104804723A (en) * | 2014-01-28 | 2015-07-29 | 中国科学院大连化学物理研究所 | DCDHF chromophore-based solvatochromic fluorescence probes, and preparation method and application thereof |
WO2016183131A1 (en) * | 2015-05-11 | 2016-11-17 | Purdue Research Foundation | Ligand ionophore conjugates |
CN107557000A (en) * | 2017-11-14 | 2018-01-09 | 浙江工业大学 | Class A3B-type asymmetric metal platinum porphyrin organic luminescent material and application thereof |
WO2018094035A3 (en) * | 2016-11-16 | 2018-06-28 | Purdue Research Foundation | Ligand ionophore conjugates |
CN109876157A (en) * | 2019-02-27 | 2019-06-14 | 浙江大学 | Ion specificity filter membrane/mesoporous silicon composite material, nano-sensor and products thereof and application |
US10590155B2 (en) | 2016-07-15 | 2020-03-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Mitochondria-targeting fluorescent potassium+ sensor and method of making the same |
US10940476B2 (en) | 2016-04-22 | 2021-03-09 | Arizona Board Of Regents On Behalf Of Arizona State University | Device for high-throughput multi-parameter functional profiling of the same cells in multicellular settings and in isolation |
US11045807B2 (en) | 2017-02-27 | 2021-06-29 | Arizona Board Of Regents On Behalf Of Arizona State University | Integrated platform for characterization of single cells or small cell clusters |
US11123740B2 (en) | 2015-06-29 | 2021-09-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis |
US11315292B2 (en) | 2017-03-02 | 2022-04-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Live-cell computed tomography |
US11327004B2 (en) | 2016-03-02 | 2022-05-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Live-cell computed tomography |
US11413616B2 (en) | 2016-11-28 | 2022-08-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods related to continuous flow droplet reaction |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020521118A (en) * | 2017-05-11 | 2020-07-16 | メディツィーニシェ・ウニフェルジテート・グラーツMedizinische Universitaet Graz | Genetically encoded potassium ion index |
CN110437268B (en) * | 2019-09-04 | 2022-01-14 | 南方科技大学 | Potassium ion probe and preparation method and application thereof |
WO2022076563A1 (en) * | 2020-10-07 | 2022-04-14 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6211359B1 (en) * | 1999-08-17 | 2001-04-03 | Avl Medical Instruments | Triaza-cryptand and method of determining an alkali ion |
WO2007006454A1 (en) * | 2005-07-07 | 2007-01-18 | F. Hoffmann-La Roche Ag | Method for the determination of the concentration of a non-volatile analyte |
WO2007044866A2 (en) * | 2005-10-11 | 2007-04-19 | The Regents Of The University Of California | Water-soluble, fluorescent compounds for detection of potassium ions |
WO2007131042A2 (en) * | 2006-05-03 | 2007-11-15 | Opti Medical Systems, Inc | Chromoionophore and method of determining potassium ions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641684A (en) | 1991-12-18 | 1997-06-24 | Johnson & Johnson Clinical Diagnostics, Inc. | Ion-sensitive dyes |
AU751168B2 (en) | 1999-04-23 | 2002-08-08 | Molecular Probes, Inc. | Xanthene dyes and their application as luminescence quenching compounds |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
US7208121B2 (en) | 2001-12-06 | 2007-04-24 | Auburn University | Plasticizer-free-ion-detective sensors |
AU2003294229A1 (en) | 2002-10-11 | 2004-05-04 | Case Western Reserve University | Sliver type autonomous biosensors |
US7390462B2 (en) | 2002-12-17 | 2008-06-24 | The University Of Maryland Baltimore County | Ratiometric fluorescent pH sensor for non-invasive monitoring |
EP1634051A4 (en) | 2003-05-28 | 2009-03-25 | Univ Auburn | Ion-detecting sensors comprising plasticizer-free copolymers |
-
2012
- 2012-02-13 US US13/985,260 patent/US9181375B2/en active Active
- 2012-02-13 WO PCT/US2012/024856 patent/WO2012112440A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6211359B1 (en) * | 1999-08-17 | 2001-04-03 | Avl Medical Instruments | Triaza-cryptand and method of determining an alkali ion |
WO2007006454A1 (en) * | 2005-07-07 | 2007-01-18 | F. Hoffmann-La Roche Ag | Method for the determination of the concentration of a non-volatile analyte |
WO2007044866A2 (en) * | 2005-10-11 | 2007-04-19 | The Regents Of The University Of California | Water-soluble, fluorescent compounds for detection of potassium ions |
WO2007131042A2 (en) * | 2006-05-03 | 2007-11-15 | Opti Medical Systems, Inc | Chromoionophore and method of determining potassium ions |
Non-Patent Citations (1)
Title |
---|
CARPENTER, R. D. ET AL.: 'Function-Oriented Synthesis of a Didesmethyl Triazacryptand Analogue for Fluorescent Potassium Ion Sensing' EUROPEAN JOURNAL OF ORGANIC CHEMISTRY vol. 2011, no. ISS.7, 17 January 2011, pages 1242 - 1248 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104804723A (en) * | 2014-01-28 | 2015-07-29 | 中国科学院大连化学物理研究所 | DCDHF chromophore-based solvatochromic fluorescence probes, and preparation method and application thereof |
WO2016183131A1 (en) * | 2015-05-11 | 2016-11-17 | Purdue Research Foundation | Ligand ionophore conjugates |
US10406238B2 (en) | 2015-05-11 | 2019-09-10 | Purdue Research Foundation | Ligand ionophore conjugates |
US12070754B2 (en) | 2015-06-29 | 2024-08-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis |
US11618030B2 (en) | 2015-06-29 | 2023-04-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis |
US11123740B2 (en) | 2015-06-29 | 2021-09-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis |
US11327004B2 (en) | 2016-03-02 | 2022-05-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Live-cell computed tomography |
US10940476B2 (en) | 2016-04-22 | 2021-03-09 | Arizona Board Of Regents On Behalf Of Arizona State University | Device for high-throughput multi-parameter functional profiling of the same cells in multicellular settings and in isolation |
US10590155B2 (en) | 2016-07-15 | 2020-03-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Mitochondria-targeting fluorescent potassium+ sensor and method of making the same |
WO2018094035A3 (en) * | 2016-11-16 | 2018-06-28 | Purdue Research Foundation | Ligand ionophore conjugates |
US11413616B2 (en) | 2016-11-28 | 2022-08-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods related to continuous flow droplet reaction |
US11607689B2 (en) | 2016-11-28 | 2023-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods related to continuous flow droplet reaction |
US11045807B2 (en) | 2017-02-27 | 2021-06-29 | Arizona Board Of Regents On Behalf Of Arizona State University | Integrated platform for characterization of single cells or small cell clusters |
US11315292B2 (en) | 2017-03-02 | 2022-04-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Live-cell computed tomography |
CN107557000A (en) * | 2017-11-14 | 2018-01-09 | 浙江工业大学 | Class A3B-type asymmetric metal platinum porphyrin organic luminescent material and application thereof |
CN107557000B (en) * | 2017-11-14 | 2020-04-24 | 浙江工业大学 | Class A3B-type asymmetric metal platinum porphyrin organic luminescent material and application thereof |
CN109876157A (en) * | 2019-02-27 | 2019-06-14 | 浙江大学 | Ion specificity filter membrane/mesoporous silicon composite material, nano-sensor and products thereof and application |
CN109876157B (en) * | 2019-02-27 | 2020-12-15 | 浙江大学 | Composite material of ion-specific filter membrane/mesoporous silicon, nano sensor, product of nano sensor and application of nano sensor |
Also Published As
Publication number | Publication date |
---|---|
US20140200319A1 (en) | 2014-07-17 |
US9181375B2 (en) | 2015-11-10 |
WO2012112440A3 (en) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9181375B2 (en) | Fluorescent potassium ion sensors | |
Liu et al. | Responsive polymers-based dual fluorescent chemosensors for Zn2+ ions and temperatures working in purely aqueous media | |
Tian et al. | A series of naphthalimide derivatives as intra and extracellular pH sensors | |
Zhou et al. | Triazacryptand-based fluorescent sensors for extracellular and intracellular K+ sensing | |
Chang et al. | ZP8, a neuronal zinc sensor with improved dynamic range; imaging zinc in hippocampal slices with two-photon microscopy | |
Cambre et al. | Biomedical applications of boronic acid polymers | |
US8129111B2 (en) | Fluorescent water-soluable conjugated polyene compounds that exhibit aggregation induced emission and methods of making and using same | |
He et al. | Sensing and intracellular imaging of Zn2+ based on affinity peptide using an aggregation induced emission fluorescence “switch-on” probe | |
Fang et al. | Asymmetric fluorescence quenching of dual-emissive porphyrin-containing conjugated polyelectrolytes for naked-eye mercury ion detection | |
Li et al. | Selective tracking of lysosomal Cu2+ ions using simultaneous target-and location-activated fluorescent nanoprobes | |
Jiang et al. | Reactive fluorescence turn-on probes for fluoride ions in purely aqueous media fabricated from functionalized responsive block copolymers | |
Wang et al. | Ratiometric imaging of lysosomal hypochlorous acid enabled by FRET-based polymer dots | |
US11199537B2 (en) | Temperature-sensitive fluorescent probe for introduction into cell | |
Yu et al. | Dual-emissive nanohybrid for ratiometric luminescence and lifetime imaging of intracellular hydrogen sulfide | |
Sayed et al. | Naphthalimide-based multifunctional AIEgens: Selective, fast, and wash-free fluorescence tracking and identification of Gram-positive bacteria | |
CN108350479B (en) | Intracellular delivery vehicle | |
JP2011511755A (en) | Polyviologen boronic acid quencher for use in an analyte sensor | |
Chen et al. | Design and fabrication of fluorescence resonance energy transfer-mediated fluorescent polymer nanoparticles for ratiometric sensing of lysosomal pH | |
Choudhury et al. | Rhodamine-appended polymeric probe: an efficient colorimetric and fluorometric sensing platform for Hg2+ in aqueous medium and living cells | |
US8679738B2 (en) | Water-soluble AIE luminogen for monitoring and retardation of amyloid fibrillation of insulin | |
El Kaoutit et al. | Chromogenic and fluorogenic detection of cations in aqueous media by means of an acrylic polymer chemosensor with pendant Rhodamine-based dyes | |
US20060020182A1 (en) | Saccharide-measuring fluorescent monomer, saccharide-measuring fluorescent sensor substance, and implantable, saccharide-measuring sensor | |
CN111936637B (en) | Oligonucleotide functionalized hydrophobic polymer nanoparticles | |
Zhao et al. | Highly efficient ratiometric extracellular oxygen sensors through physical incorporation of a conjugated polymer and PtTFPP in graft copolymers | |
Vokatá et al. | Synthesis of phenyleneethynylene-doped poly (p-phenylenebutadiynylene) s for live cell imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12746787 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12746787 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13985260 Country of ref document: US |